<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1108" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1108/" /><meta name="ncbi_pagename" content="Autoimmune Lymphoproliferative Syndrome - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Autoimmune Lymphoproliferative Syndrome - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Autoimmune Lymphoproliferative Syndrome" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2017/08/24" /><meta name="citation_author" content="Jack JH Bleesing" /><meta name="citation_author" content="Chinmayee B Nagaraj" /><meta name="citation_author" content="Kejian Zhang" /><meta name="citation_pmid" content="20301287" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1108/" /><meta name="citation_keywords" content="ALPS" /><meta name="citation_keywords" content="ALPS" /><meta name="citation_keywords" content="Canale-Smith Syndrome" /><meta name="citation_keywords" content="Caspase-10" /><meta name="citation_keywords" content="Tumor necrosis factor ligand superfamily member 6" /><meta name="citation_keywords" content="Tumor necrosis factor receptor superfamily member 6" /><meta name="citation_keywords" content="CASP10" /><meta name="citation_keywords" content="FAS" /><meta name="citation_keywords" content="FASLG" /><meta name="citation_keywords" content="Autoimmune Lymphoproliferative Syndrome" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Autoimmune Lymphoproliferative Syndrome" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Jack JH Bleesing" /><meta name="DC.Contributor" content="Chinmayee B Nagaraj" /><meta name="DC.Contributor" content="Kejian Zhang" /><meta name="DC.Date" content="2017/08/24" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1108/" /><meta name="description" content="Autoimmune lymphoproliferative syndrome (ALPS), caused by defective lymphocyte homeostasis, is characterized by the following:" /><meta name="og:title" content="Autoimmune Lymphoproliferative Syndrome" /><meta name="og:type" content="book" /><meta name="og:description" content="Autoimmune lymphoproliferative syndrome (ALPS), caused by defective lymphocyte homeostasis, is characterized by the following:" /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1108/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/alps/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1108/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8A1EE9E0414151000000000952036A.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1108_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1108_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/au-kline/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/peaf/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1108_"><span class="title" itemprop="name">Autoimmune Lymphoproliferative Syndrome</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonym: ALPS</div><p class="contrib-group"><span itemprop="author">Jack JH Bleesing</span>, MD, PhD, <span itemprop="author">Chinmayee B Nagaraj</span>, MS, CGC, and <span itemprop="author">Kejian Zhang</span>, MD, MBA.</p><a data-jig="ncbitoggler" href="#__NBK1108_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1108_ai__"><div class="contrib half_rhythm"><span itemprop="author">Jack JH Bleesing</span>, MD, PhD<div class="affiliation small">Professor of Pediatrics, Division of Bone Marrow Transplantation &#x00026; Immune Deficiency<br />Cincinnati Children's Hospital<br />Cincinnati, Ohio<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gro.cmhcc@gniseelb.kcaj" class="oemail">gro.cmhcc@gniseelb.kcaj</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Chinmayee B Nagaraj</span>, MS, CGC<div class="affiliation small">Genetic Counselor, Division of Human Genetics<br />Cincinnati Children's Hospital<br />Cincinnati, Ohio<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gro.cmhcc@oaramihb.eeyamnihc" class="oemail">gro.cmhcc@oaramihb.eeyamnihc</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Kejian Zhang</span>, MD, MBA<div class="affiliation small">Associate Professor of Pediatrics, Division of Human Genetics<br />Cincinnati Children's Hospital<br />Cincinnati, Ohio<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gro.cmhcc@gnahz.naijek" class="oemail">gro.cmhcc@gnahz.naijek</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">September 14, 2006</span>; Last Update: <span itemprop="dateModified">August 24, 2017</span>.</p><p><em>Estimated reading time: 44 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="alps.Summary" itemprop="description"><h2 id="_alps_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Autoimmune lymphoproliferative syndrome (ALPS), caused by defective lymphocyte homeostasis, is characterized by the following:</p><ul><li class="half_rhythm"><div>Non-malignant lymphoproliferation (lymphadenopathy, hepatosplenomegaly with or without hypersplenism) that often improves with age</div></li><li class="half_rhythm"><div>Autoimmune disease, mostly directed toward blood cells</div></li><li class="half_rhythm"><div>Lifelong increased risk for both Hodgkin and non-Hodgkin lymphoma</div></li></ul><p>In ALPS-FAS (the most common and best-characterized type of ALPS, associated with <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> pathogenic variants in <i>FAS</i>), non-malignant lymphoproliferation typically manifests in the first years of life, inexplicably waxes and wanes, and then often decreases without treatment in the second decade of life; in many <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals, however, neither splenomegaly nor the overall expansion of lymphocyte subsets in peripheral blood decreases. Although autoimmunity is often not present at the time of diagnosis or at the time of the most extensive lymphoproliferation, autoantibodies can be detected before autoimmune disease manifests clinically.</p><p>In ALPS-FAS caused by <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> or <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> (<a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a>) pathogenic variants in <i>FAS</i>, severe lymphoproliferation occurs before, at, or shortly after birth, and usually results in death at an early age.</p><p>ALPS-sFAS, resulting from somatic <i>FAS</i> pathogenic variants in selected cell populations, notably the alpha/beta double-negative T cells (&#x003b1;/&#x003b2;-DNT cells), appears to be similar to ALPS-FAS resulting from <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> pathogenic variants in <i>FAS</i>, although lower incidence of splenectomy and lower lymphocyte counts have been reported in ALPS-sFAS and no cases of lymphoma have yet been published.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of ALPS is based on the following:</p><ul><li class="half_rhythm"><div class="half_rhythm">Clinical findings</div></li><li class="half_rhythm"><div class="half_rhythm">Laboratory abnormalities:</div><ul><li class="half_rhythm"><div>Abnormal biomarker testing (soluble interleukin-10 [IL-10], Fas ligand [FasL], IL-18, and vitamin B<sub>12</sub>)</div></li><li class="half_rhythm"><div>Defective in vitro tumor necrosis factor receptor superfamily member 6 (Fas)-mediated apoptosis</div></li><li class="half_rhythm"><div>T cells that express the alpha/beta T-cell receptor but lack both CD4 and CD8 (so-called "&#x003b1;/&#x003b2;-DNT cells")</div></li></ul></li><li class="half_rhythm"><div class="half_rhythm">Identification of pathogenic variants in genes relevant for the Fas pathway of apoptosis. These genes include <i>FAS</i> (either <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> or somatic pathogenic variants), <i>CASP10</i>, and <i>FASGL</i>.</div><div class="half_rhythm">Up to 20% of those with clinical ALPS have not had a genetic etiology identified.</div></li></ul></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Current management is focused on monitoring for and treatment of lymphoproliferation, hypersplensim, and lymphomas and management of cytopenias and other autoimmune diseases. Corticosteroids and immunosuppressive therapy do not decrease lymphadenopathy long term and are generally reserved for severe complications of lymphoproliferation (e.g., airway obstruction, significant hypersplenism associated with splenomegaly) and/or autoimmune manifestations. Experience with sirolimus suggests that it is the preferred agent in treating lymphoproliferation in a more sustained manner, including maintenance of remission following a period of discontinued use of sirolimus; however, sirolimus is not without side effects. Lymphoma is treated with conventional protocols. Autoimmune cytopenias and other autoimmune diseases are typically treated by immune suppression with corticosteroids as well as corticosteroid-sparing agents if prolonged treatment of autoimmune cytopenias is required and/or in cases of refractory cytopenias.</p><p>Splenectomy is reserved as an option of last resort in the treatment of life-threatening refractory cytopenias and/or severe hypersplenia because of the high risk of recurrence of cytopenias and sepsis post-splenectomy in persons with ALPS.</p><p><i>Prevention of primary manifestations:</i> Bone marrow (hematopoietic stem cell) transplantation (BMT/HSCT), the only curative treatment for ALPS, has to date mostly been performed on those with severe clinical phenotypes such as ALPS-FAS caused by <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants, those with severe and/or refractory autoimmune cytopenias, those with lymphoma, and those who have developed complications from (often long-term) immunosuppressive therapy.</p><p><i>Prevention of secondary complications:</i> Vaccinations pre-splenectomy (with consideration of post-splenectomy boost vaccinations) and penicillin prophylaxis are strongly recommended for individuals who undergo splenectomy.</p><p><i>Surveillance:</i> Clinical assessment and imaging and laboratory studies for manifestations of lymphoproliferation and autoimmunity; specialized imaging studies to detect malignant transformation.</p><p><i>Agents/circumstances to avoid:</i> Splenectomy is discouraged as it typically does not lead to permanent remission of autoimmunity and is associated with increased risk of infection. Aspirin and other nonsteroidal anti-inflammatory drugs should be used with caution in individuals with immune thrombocytopenia as they can interfere with platelet function.</p><p><i>Evaluation of relatives at risk:</i> If the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>(s) have been identified in a family member with ALPS, it is appropriate to perform <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> on at-risk relatives to allow for early diagnosis and treatment.</p><p><i>Pregnancy management:</i> Assessment of the risks and benefits of treating a woman who has ALPS with corticosteroids, mycophenylate mofitil, or sirolimus during pregnancy must take into consideration the potential teratogenic risks to the fetus.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>Inheritance of ALPS-CASP10, most cases of ALPS-FAS, and some cases of ALPS-FASLG is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>. Each child of an individual with autosomal dominant ALPS has a 50% chance of inheriting the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. Inheritance of most cases of ALPS-FASLG and severe ALPS associated with <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>FAS</i> pathogenic variants is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>. The parents of an individual with autosomal recessive ALPS are likely to be heterozygotes, in which case each has one <i>FAS</i> pathogenic variant; these parents may have ALPS-related findings or may be clinically asymptomatic.</p><p>Prenatal diagnosis for pregnancies at increased risk is possible if the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>(s) have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member.</p><p>ALPS-FAS can also be the result of <a class="def" href="/books/n/gene/glossary/def-item/somatic-mosaicism/">somatic mosaicism</a>. Somatic pathogenic variants have not been reported in ALPS-FASLG or ALPS-CASP10 to date.</p></div></div><div id="alps.Diagnosis"><h2 id="_alps_Diagnosis_">Diagnosis</h2><div id="alps.Suggestive_Findings"><h3>Suggestive Findings</h3><p>The diagnosis of autoimmune lymphoproliferative syndrome (ALPS) is based on a constellation of clinical findings, laboratory abnormalities, and identification of pathogenic variants in genes relevant for the tumor necrosis factor receptor superfamily member 6 (Fas) pathway of apoptosis.</p><p>ALPS <b>should be suspected</b> in individuals with combinations of the following [<a class="bk_pop" href="#alps.REF.bleesing.2003.265">Bleesing 2003</a>, <a class="bk_pop" href="#alps.REF.rieuxlaucat.2003.325">Rieux-Laucat et al 2003</a>]:</p><ul><li class="half_rhythm"><div>Chronic non-malignant lymphoproliferation</div><ul><li class="half_rhythm"><div>Chronic and/or recurrent lymphadenopathy</div></li><li class="half_rhythm"><div>Splenomegaly with/without hypersplenism</div></li><li class="half_rhythm"><div>Hepatomegaly</div></li><li class="half_rhythm"><div>Lymphocytic interstitial pneumonia (less common)</div></li></ul></li><li class="half_rhythm"><div>Autoimmune disease</div><ul><li class="half_rhythm"><div class="half_rhythm">Cytopenia, particularly combinations of autoimmune hemolytic anemia (AIHA), immune thrombocytopenia (ITP), and autoimmune neutropenia</div><div class="half_rhythm">Note: The combination of AIHA and ITP is often referred to as Evans syndrome.</div></li><li class="half_rhythm"><div class="half_rhythm">Other, including autoimmune hepatitis, autoimmune glomerulonephritis, autoimmune thyroiditis and (less commonly) uveitis and Guillain-Barr&#x000e9; syndrome</div></li></ul></li><li class="half_rhythm"><div>Lymphoma, both Hodgkin lymphoma and non-Hodgkin lymphoma</div></li><li class="half_rhythm"><div>Skin rashes, often but not exclusively of an urticarial nature</div></li><li class="half_rhythm"><div>Family history of ALPS or ALPS-like features</div></li></ul></div><div id="alps.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of ALPS <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> who meets the clinical diagnostic criteria, which may include identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> or <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in one of the genes listed in <a class="figpopup" href="/books/NBK1108/table/alps.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figalpsTmoleculargenetictestingusedin" rid-ob="figobalpsTmoleculargenetictestingusedin">Table 1</a>.</p><p>A revised set of diagnostic criteria have been proposed [<a class="bk_pop" href="#alps.REF.oliveira.2010.e35">Oliveira et al 2010</a>]:</p><ul><li class="half_rhythm"><div>A <b>definitive</b> diagnosis of ALPS is based on the presence of both required criteria and one primary accessory criterion (see following).</div></li><li class="half_rhythm"><div>A <b>probable</b> diagnosis is based on the presence of both required criteria plus one secondary accessory criterion.</div></li></ul><p><b>Required criteria</b></p><ul><li class="half_rhythm"><div>Chronic (&#x0003e;6 months) non-malignant, noninfectious lymphadenopathy and/or splenomegaly</div></li><li class="half_rhythm"><div>Elevated &#x003b1;/&#x003b2;-DNT cells with normal or elevated lymphocyte counts</div></li></ul><p><b>Primary accessory criteria</b></p><ul><li class="half_rhythm"><div>Defective lymphocyte apoptosis (repeated at least once)</div></li><li class="half_rhythm"><div>Germline or somatic pathogenic variants in <i>CASP10</i>, <i>FAS</i>, or <i>FASLG</i></div></li></ul><p><b>Secondary accessory criteria</b></p><ul><li class="half_rhythm"><div>Elevated levels of one of the following:</div><ul><li class="half_rhythm"><div>Plasma soluble FASL</div></li><li class="half_rhythm"><div>Plasma interleukin-10</div></li><li class="half_rhythm"><div>Serum vitamin B<sub>12</sub></div></li><li class="half_rhythm"><div>Plasma interleukin-18</div></li></ul></li><li class="half_rhythm"><div>Typical immunohistologic findings as determined by an experienced hematopathologist</div></li><li class="half_rhythm"><div>Autoimmune cytopenias with elevated (polyclonal) immunoglobulin G levels</div></li><li class="half_rhythm"><div>Positive family history</div></li></ul><div id="alps.Laboratory_Findings"><h4>Laboratory Findings</h4><p>Although no specific laboratory abnormality alone is diagnostic of ALPS, the detection of the following facilitates the diagnosis [<a class="bk_pop" href="#alps.REF.bleesing.2003.265">Bleesing 2003</a>, <a class="bk_pop" href="#alps.REF.mageruschatinet.2009.3027">Magerus-Chatinet et al 2009</a>, <a class="bk_pop" href="#alps.REF.caminha.2010.946">Caminha et al 2010</a>, <a class="bk_pop" href="#alps.REF.oliveira.2010.e35">Oliveira et al 2010</a>, <a class="bk_pop" href="#alps.REF.rensingehl.2013.1948">Rensing-Ehl et al 2013</a>]:</p><ul><li class="half_rhythm"><div>Defective Fas-mediated apoptosis in vitro</div></li><li class="half_rhythm"><div>T cells that express the alpha/beta T-cell receptor but lack both CD4 and CD8 (so-called alpha/beta double-negative T cells [&#x003b1;/&#x003b2;-DNT cells] in peripheral blood or tissue specimens). Detected by flow cytometric immunophenotyping, these terminally differentiated in vivo-activated T cells are rare in healthy individuals and other immune-mediated (lymphoproliferative) disorders; typically they constitute less than 2% of the lymphocyte pool.</div></li><li class="half_rhythm"><div>Increased levels of the ALPS-specific biomarkers: soluble IL-10, IL-18, FasL, and vitamin B<sub>12</sub> in plasma/serum [<a class="bk_pop" href="#alps.REF.bowen.2012.490">Bowen et al 2012</a>]</div></li></ul><p><b>Secondary laboratory findings in ALPS</b> [<a class="bk_pop" href="#alps.REF.lim.1998.1541">Lim et al 1998</a>, <a class="bk_pop" href="#alps.REF.carter.2000.943">Carter et al 2000</a>, <a class="bk_pop" href="#alps.REF.bleesing.2001.2466">Bleesing et al 2001</a>,<a class="bk_pop" href="#alps.REF.bleesing.2003.265">Bleesing 2003</a>, <a class="bk_pop" href="#alps.REF.bleesing.2005.571">Bleesing 2005</a>, <a class="bk_pop" href="#alps.REF.maric.2005.903">Maric et al 2005</a>, <a class="bk_pop" href="#alps.REF.mageruschatinet.2009.3027">Magerus-Chatinet et al 2009</a>, <a class="bk_pop" href="#alps.REF.caminha.2010.946">Caminha et al 2010</a>, <a class="bk_pop" href="#alps.REF.oliveira.2010.e35">Oliveira et al 2010</a>, <a class="bk_pop" href="#alps.REF.bowen.2012.490">Bowen et al 2012</a>, <a class="bk_pop" href="#alps.REF.neven.2014.1597">Neven et al 2014</a>]:</p><ul><li class="half_rhythm"><div>Hematology</div><ul><li class="half_rhythm"><div>Lymphocytosis, lymphopenia (primary or secondary in response to treatment)</div></li><li class="half_rhythm"><div>Coombs-positive hemolytic anemia</div></li><li class="half_rhythm"><div>Dyserythropoiesis</div></li><li class="half_rhythm"><div>Reticulocytosis</div></li><li class="half_rhythm"><div>Thrombocytopenia</div></li><li class="half_rhythm"><div>Neutropenia</div></li><li class="half_rhythm"><div>Eosinophilia</div></li></ul></li><li class="half_rhythm"><div>Immunology</div><ul><li class="half_rhythm"><div>Expansion of other lymphocyte subsets</div><ul><li class="half_rhythm"><div>Gamma/delta-DNT cells</div></li><li class="half_rhythm"><div>CD8+/CD57+ T cells</div></li><li class="half_rhythm"><div>HLA-DR+ T cells</div></li><li class="half_rhythm"><div>CD5+ B cells</div></li></ul></li><li class="half_rhythm"><div>Decreased numbers of CD4+/CD25+ T cells</div></li><li class="half_rhythm"><div>Decreased numbers of CD27+ B cells</div></li><li class="half_rhythm"><div>Elevated concentration of IL-10 and IL-18 in serum/plasma</div></li><li class="half_rhythm"><div>Elevated concentrations of IgG, IgA, and IgE; normal or decreased concentrations of IgM</div></li><li class="half_rhythm"><div>Autoantibodies (most often positive direct or indirect antiglobulin test, antiplatelet antibody, antineutrophil antibody, antiphospholipid antibody, antinuclear antibody, rheumatoid factor)</div></li><li class="half_rhythm"><div>Lymph node pathology (paracortical expansion with immunoblasts/plasma cells and DNT cells in interfollicular areas, florid follicular hyperplasia, progressive transformation of germinal centers [PTGC])</div></li></ul></li><li class="half_rhythm"><div>Other</div><ul><li class="half_rhythm"><div>Increased soluble CD25 (sIL-2R alpha), CD27, CD30, and Fas ligand (FasL)</div></li><li class="half_rhythm"><div>Monoclonal gammopathy</div></li><li class="half_rhythm"><div>Decreased antibody responses to polysaccharide antigens [<a class="bk_pop" href="#alps.REF.neven.2014.1597">Neven et al 2014</a>]</div></li></ul></li><li class="half_rhythm"><div>Chemistry</div><ul><li class="half_rhythm"><div>Liver function abnormalities (in case of autoimmune hepatitis)</div></li><li class="half_rhythm"><div>Proteinuria (in case of glomerulonephritis)</div></li><li class="half_rhythm"><div>Elevated serum concentration of vitamin B<sub>12</sub></div></li></ul></li></ul><p><b>Normal findings in (typical) ALPS</b></p><ul><li class="half_rhythm"><div>Neutrophil function</div></li><li class="half_rhythm"><div>Complement factors concentrations and function</div></li><li class="half_rhythm"><div>In vitro proliferative responses of T cells (e.g., in response to common mitogens and antigens)</div></li><li class="half_rhythm"><div>NK-cell and cytotoxic T-lymphocyte (CTL) function; possibly decreased CTL activity in ALPS on the basis of defective FasL (i.e., ALPS-FASLG).</div></li><li class="half_rhythm"><div>Antibody responses to protein antigens (e.g., diphtheria, tetanus)</div></li></ul><p>Note: (1) The abnormal and normal laboratory findings listed have been most reliably established for individuals with ALPS caused by either <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> or somatic pathogenic variants in <i>FAS</i>. (2) Cell surface expression of Fas (CD95) can be normal, increased, or decreased and is in general not helpful in the diagnosis of ALPS. (3) When interpreting laboratory data of individuals with (suspected) ALPS, the influence of concurrent immunosuppressive agents at the time of testing needs to be considered.</p></div><div id="alps.Molecular_Genetic_Testing"><h4>Molecular Genetic Testing</h4><p>Molecular genetic testing approaches can include <b>serial single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b>, use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>, and <b>more comprehensive</b>
<b><a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b>.</p><p><b>Serial single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Sequence analysis of the gene of interest is performed first and followed by gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> if no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found.</p><ul><li class="half_rhythm"><div>For this disorder, it is recommended that <i>FAS</i> be tested first. See <a class="figpopup" href="/books/NBK1108/figure/alps.F1/?report=objectonly" target="object" rid-figpopup="figalpsF1" rid-ob="figobalpsF1">Figure 1</a> for algorithm.</div></li><li class="half_rhythm"><div>In the absence of a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>FAS</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, <i>FAS</i> sequencing in sorted &#x003b1;/&#x003b2;-DNT cells to detect somatic pathogenic variants should be performed. If present, the diagnosis of ALPS-sFAS is established.</div></li><li class="half_rhythm"><div>If neither a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> nor a somatic <i>FAS</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is identified, <i>CASP10</i> and <i>FASLG</i> should be tested next<i>.</i> The detection of germline pathogenic variants in either <i>CASP10</i> or <i>FASLG</i> establishes the diagnosis of ALPS-CASP10 or ALPS-FASLG, respectively.</div></li><li class="half_rhythm"><div>A Fas-mediated apoptosis assay should be performed if <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> pathogenic variants in <i>CASP10</i> or <i>FASLG</i> are not identified (repeat if necessary, noting the influence of concomitant immunosuppressive therapy). If abnormal, the diagnosis of ALPS-U is established.</div></li></ul><div class="iconblock whole_rhythm clearfix ten_col fig" id="figalpsF1" co-legend-rid="figlgndalpsF1"><a href="/books/NBK1108/figure/alps.F1/?report=objectonly" target="object" title="Figure 1. " class="img_link icnblk_img figpopup" rid-figpopup="figalpsF1" rid-ob="figobalpsF1"><img class="small-thumb" src="/books/NBK1108/bin/alps-Image001.gif" src-large="/books/NBK1108/bin/alps-Image001.jpg" alt="Figure 1. " /></a><div class="icnblk_cntnt" id="figlgndalpsF1"><h4 id="alps.F1"><a href="/books/NBK1108/figure/alps.F1/?report=objectonly" target="object" rid-ob="figobalpsF1">Figure 1. </a></h4><p class="float-caption no_bottom_margin">One proposed algorithm for the diagnostic evaluation of an individual suspected of having ALPS </p></div></div><p>Notes: (1) Absence of a positive family history is suggestive of ALPS-sFAS. (2) Loss of heterozygosity of <i>FAS</i> pathogenic variants has been observed in blood cells. (3) <i>FAS</i> somatic pathogenic variants in selected cell populations, including &#x003b1;/&#x003b2;-DNT cells, produce a <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> similar to that caused by <i>FAS</i> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> pathogenic variants. (4) The presence of elevated biomarkers has not been reliably established in <i>CASP10</i> or <i>FASLG-</i>related ALPS. (5) Thus far, somatic pathogenic variants in <i>FAS</i> only have been reported to cause ALPS; however, it is theoretically possible that somatic pathogenic variants in <i>CASP10</i> and <i>FASLG</i> may also be causative.</p><p><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>CASP10</i>, <i>FAS</i>, <i>FASLG</i>, and other genes of interest (see <a href="#alps.Differential_Diagnosis">Differential Diagnosis</a>) may also be considered. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</p><p>For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</p><p><b>More comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (when available) including <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a> and <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a> may be considered. Such testing may provide or suggest a diagnosis not previously considered (e.g., mutation of a different <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> or genes that results in a similar clinical presentation).</p><p>For an introduction to comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</p><div id="alps.T.molecular_genetic_testing_used_in" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in ALPS</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1108/table/alps.T.molecular_genetic_testing_used_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__alps.T.molecular_genetic_testing_used_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_alps.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_alps.T.molecular_genetic_testing_used_in_1_1_1_1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_alps.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_alps.T.molecular_genetic_testing_used_in_1_1_1_2" style="text-align:left;vertical-align:middle;">ALPS Type</th><th id="hd_h_alps.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="2" scope="col" colspan="1" headers="hd_h_alps.T.molecular_genetic_testing_used_in_1_1_1_3" style="text-align:left;vertical-align:middle;">Proportion of ALPS Attributed to Pathogenic Variants in This Gene</th><th id="hd_h_alps.T.molecular_genetic_testing_used_in_1_1_1_4" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Proportion of Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by This Method&#x000a0;<sup>3</sup></th></tr><tr><th headers="hd_h_alps.T.molecular_genetic_testing_used_in_1_1_1_4" id="hd_h_alps.T.molecular_genetic_testing_used_in_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>4</sup></th><th headers="hd_h_alps.T.molecular_genetic_testing_used_in_1_1_1_4" id="hd_h_alps.T.molecular_genetic_testing_used_in_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>5</sup></th></tr></thead><tbody><tr><td headers="hd_h_alps.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>CASP10</i></td><td headers="hd_h_alps.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">ALPS-CASP10</td><td headers="hd_h_alps.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3%-6%&#x000a0;<sup>6,</sup>&#x000a0;<sup>7</sup></td><td headers="hd_h_alps.T.molecular_genetic_testing_used_in_1_1_1_4 hd_h_alps.T.molecular_genetic_testing_used_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5/5</td><td headers="hd_h_alps.T.molecular_genetic_testing_used_in_1_1_1_4 hd_h_alps.T.molecular_genetic_testing_used_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>8</sup></td></tr><tr><td headers="hd_h_alps.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>FAS</i></td><td headers="hd_h_alps.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">ALPS-FAS</td><td headers="hd_h_alps.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">65%-70%&#x000a0;<sup>9, 10</sup></td><td headers="hd_h_alps.T.molecular_genetic_testing_used_in_1_1_1_4 hd_h_alps.T.molecular_genetic_testing_used_in_1_1_2_1" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;90%</td><td headers="hd_h_alps.T.molecular_genetic_testing_used_in_1_1_1_4 hd_h_alps.T.molecular_genetic_testing_used_in_1_1_2_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">3%-4%</td></tr><tr><td headers="hd_h_alps.T.molecular_genetic_testing_used_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">ALPS-sFAS</td><td headers="hd_h_alps.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~15%-20%&#x000a0;<sup>11,&#x000a0;12</sup></td></tr><tr><td headers="hd_h_alps.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>FASLG</i></td><td headers="hd_h_alps.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">ALPS-FASLG</td><td headers="hd_h_alps.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;1%&#x000a0;<sup>13</sup></td><td headers="hd_h_alps.T.molecular_genetic_testing_used_in_1_1_1_4 hd_h_alps.T.molecular_genetic_testing_used_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">7/7</td><td headers="hd_h_alps.T.molecular_genetic_testing_used_in_1_1_1_4 hd_h_alps.T.molecular_genetic_testing_used_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>8</sup></td></tr><tr><td headers="hd_h_alps.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown</td><td headers="hd_h_alps.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">ALPS-U</td><td headers="hd_h_alps.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~20%&#x000a0;<sup>14</sup></td><td headers="hd_h_alps.T.molecular_genetic_testing_used_in_1_1_1_4 hd_h_alps.T.molecular_genetic_testing_used_in_1_1_2_1 hd_h_alps.T.molecular_genetic_testing_used_in_1_1_2_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:middle;">NA</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="alps.TF.1.1"><p class="no_margin">See <a href="/books/NBK1108/#alps.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="alps.TF.1.2"><p class="no_margin">See <a href="#alps.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="alps.TF.1.3"><p class="no_margin">Pathogenic variants listed in Human Gene Mutation Database (HGMD) considered to assess the proportion of variants detectable by each methodology</p></div></dd><dt>4. </dt><dd><div id="alps.TF.1.4"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>5. </dt><dd><div id="alps.TF.1.5"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods that may be used include: <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>6. </dt><dd><div id="alps.TF.1.6"><p class="no_margin">Note that of the two pathogenic variants in <i>CASP10</i> originally reported [<a class="bk_pop" href="#alps.REF.wang.1999.47">Wang et al 1999</a>], p.Val410Ile was subsequently determined not to cause ALPS [<a class="bk_pop" href="#alps.REF.zhu.2006.284">Zhu et al 2006</a>].</p></div></dd><dt>7. </dt><dd><div id="alps.TF.1.7"><p class="no_margin">In two individuals, ALPS was presumed to result from coinherited pathogenic variants in <i>FAS</i> and <i>CASP10</i> that were hypothesized to cooperate in causing ALPS [<a class="bk_pop" href="#alps.REF.cerutti.2007.28">Cerutti et al 2007</a>].</p></div></dd><dt>8. </dt><dd><div id="alps.TF.1.8"><p class="no_margin">No data on detection rate of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> are available.</p></div></dd><dt>9. </dt><dd><div id="alps.TF.1.9"><p class="no_margin">Generally <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> pathogenic variants occur in <i>FAS</i>. Homozygous / <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> <i>FAS</i> germline pathogenic variants are also observed and are typically associated with a severe <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> [<a class="bk_pop" href="#alps.REF.rieuxlaucat.1995.1347">Rieux-Laucat et al 1995</a>, <a class="bk_pop" href="#alps.REF.kasahara.1998.195">Kasahara et al 1998</a>, <a class="bk_pop" href="#alps.REF.van_der_burg.2000.336">van der Burg et al 2000</a>, <a class="bk_pop" href="#alps.REF.bleesing.2003.265">Bleesing 2003</a>, <a class="bk_pop" href="#alps.REF.rieuxlaucat.2003.325">Rieux-Laucat et al 2003</a>].</p></div></dd><dt>10. </dt><dd><div id="alps.TF.1.10"><p class="no_margin">Individuals with an inherited <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in addition to a second acquired pathogenic variant [<a class="bk_pop" href="#alps.REF.mageruschatinet.2011.106">Magerus-Chatinet et al 2011</a>], as well as individuals exhibiting somatic <a class="def" href="/books/n/gene/glossary/def-item/loss-of-heterozygosity/">loss of heterozygosity</a> [<a class="bk_pop" href="#alps.REF.mageruschatinet.2011.106">Magerus-Chatinet et al 2011</a>, <a class="bk_pop" href="#alps.REF.hauck.2013.61">Hauck et al 2013</a>], have been also described.</p></div></dd><dt>11. </dt><dd><div id="alps.TF.1.11"><p class="no_margin">Somatic pathogenic variants are observed in selected cell populations, including &#x003b1;/&#x003b2;-DNT cells [<a class="bk_pop" href="#alps.REF.holzelova.2004.1409">Holzelova et al 2004</a>, <a class="bk_pop" href="#alps.REF.r_ssler.2005.691">R&#x000f6;ssler et al 2005</a>, <a class="bk_pop" href="#alps.REF.dowdell.2010.5164">Dowdell et al 2010</a>], but rarely in other lymphocyte subsets and not in non-lymphocytes.</p></div></dd><dt>12. </dt><dd><div id="alps.TF.1.12"><p class="no_margin">Detection of <i>FAS</i> somatic pathogenic variants requires specialized genetic testing of &#x003b1;/&#x003b2;-DNT cells sorted by either flow cytometric immunophenotyping or by magnetic bead immunophenotyping.</p></div></dd><dt>13. </dt><dd><div id="alps.TF.1.13"><p class="no_margin">Homozygous or <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> pathogenic variants in <i>FASLG</i> have been reported: individuals with <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> pathogenic variants have especially severe disease [<a class="bk_pop" href="#alps.REF.mageruschatinet.2013.486">Magerus-Chatinet et al 2013</a>]. A review of reported cases identifies a total of eight cases (including 2 sibs). In five of seven probands, ALPS was associated with homozygous <i>FASLG</i> pathogenic variants and an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> inheritance pattern (see <a href="#alps.Molecular_Pathogenesis">Molecular Genetic Pathogenesis</a>).</p></div></dd><dt>14. </dt><dd><div id="alps.TF.1.14"><p class="no_margin">Approximately 20%-25% of individuals with ALPS lack a genetic diagnosis [<a class="bk_pop" href="#alps.REF.bleesing.2003.265">Bleesing 2003</a>].</p></div></dd></dl></div></div></div></div></div></div><div id="alps.Clinical_Characteristics"><h2 id="_alps_Clinical_Characteristics_">Clinical Characteristics</h2><div id="alps.Clinical_Description"><h3>Clinical Description</h3><p>Autoimmune lymphoproliferative syndrome (ALPS) can be considered a prototypic disorder of defective lymphocyte homeostasis [<a class="bk_pop" href="#alps.REF.sneller.1992.334">Sneller et al 1992</a>, <a class="bk_pop" href="#alps.REF.fisher.1995.935">Fisher et al 1995</a>, <a class="bk_pop" href="#alps.REF.rieuxlaucat.1995.1347">Rieux-Laucat et al 1995</a>].</p><p>The manifestations are lymphadenopathy, hepatosplenomegaly with or without hypersplenism, and autoimmune disease, mostly directed toward blood cells. In addition, the risk of lymphoma is increased.</p><div id="alps.Summary_of_Clinical_Manifestations"><h4>Summary of Clinical Manifestations of ALPS</h4><p><b>Lymphoproliferation of non-malignant lymphoid cells</b></p><ul><li class="half_rhythm"><div>Lymphadenopathy</div></li><li class="half_rhythm"><div>Splenomegaly (+/- hypersplenism)</div></li><li class="half_rhythm"><div>Hepatomegaly</div></li></ul><p><b>Autoimmunity</b></p><ul><li class="half_rhythm"><div>Autoimmune hemolytic anemia</div></li><li class="half_rhythm"><div>Autoimmune thrombocytopenia</div></li><li class="half_rhythm"><div>Autoimmune neutropenia</div></li><li class="half_rhythm"><div>Glomerulonephritis</div></li><li class="half_rhythm"><div>Autoimmune hepatitis</div></li><li class="half_rhythm"><div>Guillain Barr&#x000e9; syndrome</div></li><li class="half_rhythm"><div>Uveitis, iridocyclitis</div></li><li class="half_rhythm"><div>Other autoimmune disorders (in individual cases)</div></li></ul><p><b>Neoplasia (including benign tumors)</b></p><ul><li class="half_rhythm"><div>Lymphoma (Hodgkin and non-Hodgkin lymphoma)</div></li><li class="half_rhythm"><div>Carcinoma (thyroid, breast, skin, tongue, liver)</div></li><li class="half_rhythm"><div>Multiple neoplastic lesions (thyroid/breast adenomas, gliomas)</div></li></ul><p><b>Other and/or infrequent findings</b></p><ul><li class="half_rhythm"><div>Urticaria and other skin rashes</div></li><li class="half_rhythm"><div>Vasculitis</div></li><li class="half_rhythm"><div>Panniculitis</div></li><li class="half_rhythm"><div>Arthritis and arthralgia</div></li><li class="half_rhythm"><div>Recurrent oral ulcers</div></li><li class="half_rhythm"><div>Humoral immunodeficiency</div></li><li class="half_rhythm"><div>Pulmonary infiltrates</div></li><li class="half_rhythm"><div>Premature ovarian insufficiency</div></li><li class="half_rhythm"><div>Hydrops fetalis</div></li><li class="half_rhythm"><div>Organic brain syndrome (mental status changes, seizures, headaches)</div></li></ul><p>The natural history of ALPS is not well understood. While non-malignant lymphoproliferative manifestations often regress or improve over time, autoimmunity appears to show no permanent remission with advancing age. Moreover, the risk for development of lymphoma likely is lifelong. Thus, in the absence of curative treatment, the overall prognosis for ALPS remains guarded, necessitating long-term clinical studies to better understand its natural history. Two publications have provided significant new insights into the features, complications, natural history, and prognosis of ALPS. These studies are subsequently referred to in this <i>GeneReview</i> as the "French cohort" and the "NIH cohort" [<a class="bk_pop" href="#alps.REF.neven.2011.4798">Neven et al 2011</a>, <a class="bk_pop" href="#alps.REF.price.2014.1989">Price et al 2014</a>].</p></div><div id="alps.ALPSFAS"><h4>ALPS-FAS</h4><p>ALPS-FAS is the most common and best-characterized type of ALPS. The following are the main consequences of perturbed lymphocyte homeostasis in ALPS-FAS.</p><p><b>Chronic non-malignant lymphoproliferation.</b> Expansion of antigen-specific lymphocyte populations that are not eliminated through apoptosis leads to expansion of the lymphoid compartment, resulting in lymphadenopathy, splenomegaly, hypersplenism, and, less frequently, hepatomegaly. In most individuals with ALPS-FAS, this finding typically manifests in the first years of life. In some individuals, splenomegaly is the predominant or only manifestation of lymphoproliferation [<a class="bk_pop" href="#alps.REF.bleesing.2003.265">Bleesing 2003</a>, <a class="bk_pop" href="#alps.REF.rieuxlaucat.2003.325">Rieux-Laucat et al 2003</a>].</p><p>The median age of onset was three years in the French cohort and 2.7 years in the NIH cohort. Lymphadenopathy was present in 85% in the French cohort and 97% in the NIH cohort, while splenomegaly was present in 94% in the French cohort (with 73% showing hypersplenism) and 95% in the NIH cohort [<a class="bk_pop" href="#alps.REF.neven.2011.4798">Neven et al 2011</a>, <a class="bk_pop" href="#alps.REF.price.2014.1989">Price et al 2014</a>].</p><p>In many individuals, lymphadenopathy tends to decrease early in the second decade, whereas splenomegaly often does not. Furthermore, long-term follow up in several individuals has shown that diminution of lymphadenopathy is not accompanied by significant changes in the overall expansion of lymphocyte subsets in peripheral blood [<a class="bk_pop" href="#alps.REF.bleesing.2001.2466">Bleesing et al 2001</a>]. The lymphoproliferation waxes and wanes for reasons that are not entirely clear. Intercurrent viral and bacterial infections can influence lymphadenopathy, perhaps reflecting activation of other (intact) apoptosis pathways.</p><p>The overall prognosis of lymphoproliferation is relatively good; few individuals require long-term treatment with immunosuppressive agents to control lymphoproliferation [<a class="bk_pop" href="#alps.REF.bleesing.2003.265">Bleesing 2003</a>, <a class="bk_pop" href="#alps.REF.rieuxlaucat.2003.325">Rieux-Laucat et al 2003</a>, <a class="bk_pop" href="#alps.REF.neven.2011.4798">Neven et al 2011</a>, <a class="bk_pop" href="#alps.REF.price.2014.1989">Price et al 2014</a>].</p><p>Laboratory findings of lymphoproliferation show expansion of most lymphocyte subsets including the pathognomonic &#x003b1;/&#x003b2;-DNT cells as well as other T- and B-cell subsets.</p><p><b>Autoimmunity,</b> a common feature of ALPS, is often not present at the time of diagnosis or at the time of the most extensive lymphoproliferation. The reason for the delay in onset is unclear but may be related to age-dependent acquisition of secondary pathogenic factors that interact with defective Fas-mediated apoptosis. In many individuals with ALPS autoantibodies can be detected years before the appearance of clinical manifestations of autoimmune disease [<a class="bk_pop" href="#alps.REF.bleesing.2003.265">Bleesing 2003</a>, <a class="bk_pop" href="#alps.REF.rieuxlaucat.2003.325">Rieux-Laucat et al 2003</a>].</p><p>The French cohort and NIH cohort revealed that, in general, <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals with later disease onset often present with autoimmune disease, while younger individuals typically present with lymphoproliferative disease, followed by autoimmune disease, with a two- to three-year delay between lymphoproliferative disease onset and autoimmune disease onset. However, many affected individuals in both age groups presented with autoimmune disease as their first manifestation of ALPS [<a class="bk_pop" href="#alps.REF.neven.2011.4798">Neven et al 2011</a>, <a class="bk_pop" href="#alps.REF.price.2014.1989">Price et al 2014</a>].</p><p>Although autoimmune manifestations can also wax and wane, current knowledge suggests that autoimmune disease poses a lifelong burden. In the NIH cohort, 37% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals were described as having a severe autoimmune disease <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> (as determined by the presence of grade 3 or 4 cytopenias) within two years of disease onset [<a class="bk_pop" href="#alps.REF.price.2014.1989">Price et al 2014</a>].</p><p>Autoimmunity most often involves combinations of Coombs-positive hemolytic anemia and immune thrombocytopenia (together referred to as Evans syndrome); autoimmune neutropenia is less common. The observation of primary lymphopenia, contrasting with the typical presence of lymphocytosis, suggests the possibility of autoimmune lymphopenia (as seen in other autoimmune diseases).</p><p>The presence of Evans syndrome without significant lymphoproliferation can be consistent with ALPS, especially if &#x003b1;/&#x003b2;-DNT cells are present [<a class="bk_pop" href="#alps.REF.seif.2010.2142">Seif et al 2010</a>].</p><p>Autoimmune cytopenias may be difficult to distinguish from the effects of concomitant hypersplenism; examination of blood smears for evidence of hemolysis and measurement of autoantibodies and the degree of reticulocytosis may help in establishing the distinction.</p><p>Additional autoimmune features can be found, often in patterns that appear to be family specific, suggesting the influence of other (background) genetic information [<a class="bk_pop" href="#alps.REF.rieuxlaucat.1999.2575">Rieux-Laucat et al 1999</a>, <a class="bk_pop" href="#alps.REF.vaishnaw.1999.1833">Vaishnaw et al 1999</a>, <a class="bk_pop" href="#alps.REF.kanegane.2003.454">Kanegane et al 2003</a>].</p><p>Laboratory findings include among others: autoantibodies detected by direct and indirect antiglobulin tests (Coombs' test), antiplatelet antibodies, antineutrophil antibodies, antinuclear antibodies (ANA), and antiphospholipid antibodies.</p><p><b>Lymphoma.</b> Individuals with ALPS-FAS are at an increased risk for both Hodgkin and non-Hodgkin lymphoma, underscoring the role of Fas as a tumor-suppressor <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>. Based on calculations in one study, the increased risk is 14-fold and 51-fold for non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL), respectively [<a class="bk_pop" href="#alps.REF.straus.2001.194">Straus et al 2001</a>].</p><p>More recently, updated risk calculations were provided through the French cohort and the NIH cohort. The French cohort provided a 15% cumulative risk of lymphoma before age 30 years. This represented seven cases of lymphoma (3 cases of HL and 4 cases of NHL) out of a total of 90 <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals [<a class="bk_pop" href="#alps.REF.neven.2011.4798">Neven et al 2011</a>].</p><p>In the NIH cohort, 18 cases of lymphoma out of a total of 150 <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals were identified with a median age of detection of 18 years and a male-to-female ratio of 3.5 to 1. Sixteen (89%) of 18 cases were of B-cell origin. It was determined that 17/18 cases occurred in individuals with pathogenic variants affecting the death <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> of FAS. Using published expected cases of HL and NHL in the general population, the 16 cases of B-cell lymphoma conferred a standardized incidence ratio of 149 for HL and 61 for NHL. These numbers are significantly different from those previously published by the NIH group [<a class="bk_pop" href="#alps.REF.straus.2001.194">Straus et al 2001</a>, <a class="bk_pop" href="#alps.REF.price.2014.1989">Price et al 2014</a>].</p><p>Lymphoma typically originates in B cells, but has been found in T cells as well, although much less frequently (2/18 cases in the NIH cohort) [<a class="bk_pop" href="#alps.REF.price.2014.1989">Price et al 2014</a>]. Lymphoma is not related to Epstein-Barr virus (EBV) infection (based on absence of EBV in tumor biopsies).</p><p>Current experience suggests that lymphomas can occur at any age in ALPS-FAS and do respond to conventional chemotherapeutic treatment. Individuals with other forms of ALPS may also be at an increased risk for lymphoma; however, further data are needed to provide a detailed risk assessment. Because of the frequent concomitant presence of benign (i.e., "typical") lymphadenopathy and splenomegaly, distinguishing a "good" node from a "bad" node is a diagnostic challenge. Important clues are B-type symptoms including fever, night sweats, itching, and weight loss. In addition, PET-based imaging may be helpful in distinguishing "good" from "bad" nodes on the basis of presumed higher metabolic activity of malignant lymphoid tissue [<a class="bk_pop" href="#alps.REF.rao.2006.81">Rao et al 2006</a>].</p><p>A number of studies have looked at associations between Fas and neoplasms, including somatic pathogenic variants in solid tumors, leukemias, and lymphomas. For further discussion, see <a class="bk_pop" href="#alps.REF.m_schen.2002.75">M&#x000fc;schen et al [2002]</a>, <a class="bk_pop" href="#alps.REF.houston.2004.321">Houston &#x00026; O'Connell [2004]</a>, <a class="bk_pop" href="#alps.REF.poppema.2004.423">Poppema et al [2004]</a>, and <a class="bk_pop" href="#alps.REF.peter.2005.25">Peter et al [2005]</a>.</p></div><div id="alps.ALPSFAS_Caused_by_Biallelic_Pathoge"><h4>ALPS-FAS Caused by Biallelic Pathogenic Variants</h4><p><b>Chronic non-malignant lymphoproliferation.</b> Individuals with <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> or <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> <i>FAS</i> pathogenic variants often present with severe lymphoproliferation at or shortly after birth [<a class="bk_pop" href="#alps.REF.rieuxlaucat.1995.1347">Rieux-Laucat et al 1995</a>, <a class="bk_pop" href="#alps.REF.le_deist.1996.719">Le Deist et al 1996</a>, <a class="bk_pop" href="#alps.REF.kasahara.1998.195">Kasahara et al 1998</a>, <a class="bk_pop" href="#alps.REF.van_der_burg.2000.336">van der Burg et al 2000</a>].</p><p><b>Autoimmunity.</b> In several individuals reported, the delay between onset of autoimmunity and lymphoproliferation was minimal, while in others this was not the case. The rarity of and poor prognosis in ALPS-FAS resulting from <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants make it difficult to draw firm conclusions regarding autoimmunity in this type of ALPS [<a class="bk_pop" href="#alps.REF.rieuxlaucat.1995.1347">Rieux-Laucat et al 1995</a>, <a class="bk_pop" href="#alps.REF.le_deist.1996.719">Le Deist et al 1996</a>, <a class="bk_pop" href="#alps.REF.kasahara.1998.195">Kasahara et al 1998</a>, <a class="bk_pop" href="#alps.REF.van_der_burg.2000.336">van der Burg et al 2000</a>].</p><p><b>Lymphoma.</b> Because of the severity of ALPS-FAS caused by <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants, <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals typically succumb to lymphoproliferation and/or autoimmunity at an early age.</p></div><div id="alps.ALPSsFAS"><h4>ALPS-sFAS</h4><p>Somatic <i>FAS</i> pathogenic variants in selected cell populations (notably the &#x003b1;/&#x003b2;-DNT cells) have been identified in individuals with ALPS-sFAS. Individuals with somatic <i>FAS</i> pathogenic variants now constitute the second largest group of ALPS. Most of the clinical and laboratory features of ALPS-FAS are recapitulated in individuals with somatic <i>FAS</i> pathogenic variants including age of presentation, although lower incidence of splenectomy and lower lymphocyte counts have been reported in ALPS-sFAS and no cases of lymphoma have yet been published.</p><p>The population of &#x003b1;/&#x003b2;-DNT cells is expanded; however, as noted initially [<a class="bk_pop" href="#alps.REF.holzelova.2004.1409">Holzelova et al 2004</a>, <a class="bk_pop" href="#alps.REF.r_ssler.2005.691">R&#x000f6;ssler et al 2005</a>, <a class="bk_pop" href="#alps.REF.mageruschatinet.2011.106">Magerus-Chatinet et al 2011</a>], Fas-mediated apoptosis in vitro is typically not defective, although defective Fas-mediated apoptosis has been noted in some recently published cases [<a class="bk_pop" href="#alps.REF.dowdell.2010.5164">Dowdell et al 2010</a>].</p></div><div id="alps.Pathogenesis_of_ALPS"><h4>Pathogenesis of ALPS</h4><p>The <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of ALPS results from defective apoptosis of lymphocytes mediated through the Fas/Fas ligand (FasL) pathway. This pathway normally limits the size of the lymphocyte compartment by eliminating/removing autoreactive lymphocytes; therefore, defects in this pathway lead to expansion of antigen-specific lymphocyte populations. Although Fas also appears to play a role in suppression of malignant transformation of lymphocytes, it remains to be firmly established whether this involves the Fas/FasL pathway in a similar way. It should be noted that the pathogenesis of ALPS remains an ongoing topic of research.</p><p>Somatic <i>FAS</i> pathogenic variants are of particular interest in understanding the pathogenesis of ALPS, for example, with regard to the observed delay between lymphoproliferation and autoimmunity: the <a class="def" href="/books/n/gene/glossary/def-item/somatic-pathogenic-variant/">somatic pathogenic variant</a> is mostly confined to the &#x003b1;/&#x003b2;-DNT cells and typically not found (at least not in large proportion) in other lymphocyte subsets such as B cells. Perhaps this observation will help to characterize the impact of the <i>FAS</i> pathogenic variant relative to other potential pathogenic factors.</p></div></div><div id="alps.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p><b>ALPS-FAS.</b> The clinical lymphoproliferative and autoimmune <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of ALPS is associated with pathogenic variants which affect any <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> of Fas. Lymphomas, in contrast, seem thus far to be associated mostly with pathogenic variants affecting the intracellular domains of Fas, although independent confirmation is required [<a class="bk_pop" href="#alps.REF.straus.2001.194">Straus et al 2001</a>, <a class="bk_pop" href="#alps.REF.price.2014.1989">Price et al 2014</a>].</p><p>In the majority of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals, <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <i>FAS</i> pathogenic variants are associated with ALPS-FAS by the mechanism of <a class="def" href="/books/n/gene/glossary/def-item/dominant-negative/">dominant-negative</a> interference; however, with certain pathogenic variants affecting extracellular <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a>, the proposed mechanism is <a class="def" href="/books/n/gene/glossary/def-item/haploinsufficiency/">haploinsufficiency</a>. In the latter case, the ALPS clinical <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> may be less severe, linked to less defective in vitro apoptosis [<a class="bk_pop" href="#alps.REF.kuehn.2011.6035">Kuehn et al 2011</a>]. (For further discussion see Molecular Genetics, <a href="#alps.Molecular_Pathogenesis">Molecular Pathogenesis</a>.)</p><p><b>ALPS-FASLG and ALPS-CASP10.</b> Because of their rarity, <a class="def" href="/books/n/gene/glossary/def-item/genotype-phenotype-correlations/">genotype-phenotype correlations</a> are not clearly established for <i>FASLG</i> and <i>CASP10</i> pathogenic variants.</p></div><div id="alps.Penetrance"><h3>Penetrance</h3><p><b>ALPS-FAS.</b> A distinction needs to be made between the <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> of the cellular <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> (defective Fas-mediated apoptosis) and the penetrance of the clinical phenotype (i.e., ALPS).</p><p>Family studies to date suggest that <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> for the defective Fas-mediated apoptosis cellular <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> approximates 100% (i.e., every individual <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for an inherited [<a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a>] <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has defective apoptosis) whereas the penetrance for the clinical phenotype is reduced because a significant proportion of relatives heterozygous for the pathogenic variant have no clinical findings of ALPS. In addition, other relatives have laboratory findings of ALPS (e.g., expansion of lymphocyte subsets and/or autoantibodies) without clinical evidence of either lymphoproliferation or autoimmunity [<a class="bk_pop" href="#alps.REF.infante.1998.629">Infante et al 1998</a>, <a class="bk_pop" href="#alps.REF.jackson.1999.1002">Jackson et al 1999</a>, <a class="bk_pop" href="#alps.REF.bleesing.2001.2466">Bleesing et al 2001</a>].</p><p>The factors that determine the <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> of clinical ALPS are not entirely understood. Penetrance appears to be determined by the location and type of <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#alps.REF.rieuxlaucat.1999.2575">Rieux-Laucat et al 1999</a>, <a class="bk_pop" href="#alps.REF.le_deist.2004">Le Deist 2004</a>]. In initial studies, the highest penetrance (70%-90%) for the clinical <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> occurred with <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants affecting the intracellular domains (ICD), followed by variants leading to truncation of the ICDs. For pathogenic variants affecting the extracellular domains (ECD) the highest penetrance was estimated at approximately 30% [<a class="bk_pop" href="#alps.REF.jackson.1999.1002">Jackson et al 1999</a>].</p><p>In the French cohort ECD pathogenic variants had a <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> of 52% (higher than previous data) and ICD pathogenic variants had a 63% penetrance (lower than previously reported). The penetrance of <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants affecting the death <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> (part of the ICD) was 73% [<a class="bk_pop" href="#alps.REF.jackson.1999.1002">Jackson et al 1999</a>, <a class="bk_pop" href="#alps.REF.neven.2011.4798">Neven et al 2011</a>].</p><p>The reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> for ALPS in some families suggests that one or more additional pathogenic factors interact with defective Fas-mediated apoptosis. However, the high penetrance for the clinical <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> in certain families associated with specific types of <i>FAS</i> pathogenic variants (e.g., <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants affecting the death <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a>) casts doubt on that assumption, suggesting that under certain conditions a single defect in Fas-mediated apoptosis is sufficient to cause ALPS [<a class="bk_pop" href="#alps.REF.infante.1998.629">Infante et al 1998</a>, <a class="bk_pop" href="#alps.REF.jackson.1999.1002">Jackson et al 1999</a>, <a class="bk_pop" href="#alps.REF.le_deist.2004">Le Deist 2004</a>].</p><p>An observation that may shed more light on the issue of <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a>, particularly as it relates to pathogenic variants affecting intracellular vs extracellular domains (as well as on pathogenesis and natural history of ALPS): in a small subset of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals, clinical disease appeared to develop as a consequence of both an inherited <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> (<a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a>) <i>FAS</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> and a somatic genetic event in the second <i>FAS</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> [<a class="bk_pop" href="#alps.REF.mageruschatinet.2011.106">Magerus-Chatinet et al 2011</a>]. Analysis of &#x003b1;/&#x003b2;-DNT cells revealed that the second genetic event involved either a somatic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> or <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> variant in the second <i>FAS</i> allele or <a class="def" href="/books/n/gene/glossary/def-item/loss-of-heterozygosity/">loss of heterozygosity</a> by telomeric <a class="def" href="/books/n/gene/glossary/def-item/uniparental-disomy/">uniparental disomy</a> of <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> 10. These observations were recently confirmed in a family with ALPS in which affected individuals had a heterozygous germline FAS start codon variant with somatic loss of heterozygosity [<a class="bk_pop" href="#alps.REF.hauck.2013.61">Hauck et al 2013</a>].</p><p>A gender inequality in ALPS has been observed. In the French cohort, the likelihood of a male with a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>FAS</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> developing ALPS was about 75%, compared to 51% for females. In the NIH cohort the likelihood of developing ALPS for males and females was 69% and 46%, respectively. The ratio of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males to affected females was 2.2 (French cohort) and 1.6 (NIH cohort). Lastly, in the French cohort, the ratio of affected males to affected females increased from 2.2. to 2.9 if autoimmune disease was present and to 4.2 if autoimmune disease included autoimmune cytopenias [<a class="bk_pop" href="#alps.REF.neven.2011.4798">Neven et al 2011</a>, <a class="bk_pop" href="#alps.REF.price.2014.1989">Price et al 2014</a>].</p></div><div id="alps.Anticipation"><h3>Anticipation</h3><p>Anticipation has not been documented in ALPS.</p></div><div id="alps.Nomenclature"><h3>Nomenclature</h3><div id="alps.T.revised_classification_of_alps" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Revised Classification of ALPS</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1108/table/alps.T.revised_classification_of_alps/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__alps.T.revised_classification_of_alps_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_alps.T.revised_classification_of_alps_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Previously Used Term</th><th id="hd_h_alps.T.revised_classification_of_alps_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Current Term</th></tr></thead><tbody><tr><td headers="hd_h_alps.T.revised_classification_of_alps_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">ALPS0</td><td headers="hd_h_alps.T.revised_classification_of_alps_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">ALPS-FAS (caused by <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>FAS</i> pathogenic variants)</td></tr><tr><td headers="hd_h_alps.T.revised_classification_of_alps_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">ALPSIa</td><td headers="hd_h_alps.T.revised_classification_of_alps_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">ALPS-FAS (caused by <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>FAS</i> pathogenic variants)</td></tr><tr><td headers="hd_h_alps.T.revised_classification_of_alps_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">ALPSIm</td><td headers="hd_h_alps.T.revised_classification_of_alps_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">ALPS-sFAS (caused by somatic <i>FAS</i> pathogenic variants)</td></tr><tr><td headers="hd_h_alps.T.revised_classification_of_alps_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">ALPSIb</td><td headers="hd_h_alps.T.revised_classification_of_alps_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">ALPS-FASLG</td></tr><tr><td headers="hd_h_alps.T.revised_classification_of_alps_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">ALPSIIa</td><td headers="hd_h_alps.T.revised_classification_of_alps_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">ALPS-CASP10</td></tr><tr><td headers="hd_h_alps.T.revised_classification_of_alps_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">ALPSIII</td><td headers="hd_h_alps.T.revised_classification_of_alps_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">ALPS-U (no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>FAS</i>, <i>FASLG</i>, or <i>CASP10</i> identified)</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin"><a class="bk_pop" href="#alps.REF.oliveira.2010.e35">Oliveira et al [2010]</a></p></div></dd></dl></div></div></div><p>ALPS has also been referred to as Canale-Smith syndrome.</p></div><div id="alps.Prevalence"><h3>Prevalence</h3><p>Nearly 500 patients with ALPS in more than 300 families have been reported worldwide with no racial or ethnic predilection. However, the true prevalence of ALPS is still unknown as many individuals are undiagnosed or misdiagnosed [<a class="bk_pop" href="#alps.REF.shah.2014.462">Shah et al 2014</a>].</p></div></div><div id="alps.Genetically_Related_Allelic_Disorde"><h2 id="_alps_Genetically_Related_Allelic_Disorde_">Genetically Related (Allelic) Disorders</h2><p><b><i>FAS</i>, <i>FASLG</i>, and <i>CASP10</i>.</b> No <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> other than ALPS is currently known to be associated with <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> or somatic pathogenic variants in these genes.</p></div><div id="alps.Differential_Diagnosis"><h2 id="_alps_Differential_Diagnosis_">Differential Diagnosis</h2><p><b>ALPS-like disorders.</b> Pathogenic variants in genes inside (other than <i>FAS</i>, <i>FASLG</i>, and <i>CASP10</i>) and outside Fas/FasL pathway have been reported in association with clinical findings similar to ALPS. However, they either do not fulfill the current diagnostic criteria of ALPS [<a class="bk_pop" href="#alps.REF.oliveira.2010.e35">Oliveira et al 2010</a>] or have other distinct phenotypes, and therefore are listed as ALPS-like disorders. These include:</p><ul><li class="half_rhythm"><div><b>Dianzani autoimmune lymphoproliferative disease (DALD)</b> (OMIM <a href="http://omim.org/entry/605233" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">605233</a>). Individuals with DALD present with autoimmunity, lymphoproliferation, splenomegaly, and defective Fas function without expansion of DNT cells. A genetic basis for this disorder is suspected, but no associated genes have been identified to date [<a class="bk_pop" href="#alps.REF.oliveira.2010.e35">Oliveira et al 2010</a>, <a class="bk_pop" href="#alps.REF.boggio.2014.1178">Boggio et al 2014</a>].</div></li><li class="half_rhythm"><div><b>Ras-associated autoimmune leukoproliferative disorder (RALD)</b> (OMIM <a href="http://omim.org/entry/614470" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">614470</a>). RALD results from somatic <a class="def" href="/books/n/gene/glossary/def-item/gain-of-function/">gain-of-function</a> variants in <i>NRAS</i> and <i>KRAS</i>, which are present only in blood cells. Similar to ALPS, RALD is a primary immunodeficiency disorder of defective apoptosis. Abnormal apoptosis in RALD results from a defect in a secondary apoptosis pathway, rather than the FAS-mediated apoptosis pathway in ALPS. RALD is characterized by mild peripheral lymphadenopathy, (hepato)splenomegaly, and autoimmunity. Recurrent respiratory tract infections are reported in some <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals. Because of the rarity of this condition, the risk for lymphoma is not known [<a class="bk_pop" href="#alps.REF.chun.2002.395">Chun et al 2002</a>, <a class="bk_pop" href="#alps.REF.oliveira.2007.8953">Oliveira et al 2007</a>, <a class="bk_pop" href="#alps.REF.niemela.2011.2883">Niemela et al 2011</a>, <a class="bk_pop" href="#alps.REF.takagi.2011.2887">Takagi et al 2011</a>, <a class="bk_pop" href="#alps.REF.lanzarotti.2014.1960">Lanzarotti et al 2014</a>].</div></li><li class="half_rhythm"><div><b>Caspase-8 deficiency state (CEDS)</b> (OMIM <a href="http://omim.org/entry/607271" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">607271</a>). CEDS is a rare, <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> immunodeficiency syndrome resulting in lymphadenopathy, splenomegaly, marginal elevation of double-negative T cells, and defective FAS-mediated apoptosis, in addition to frequent bacterial and viral infections secondary to defective activation of T and B lymphocytes and NK cells. Autoimmunity has not been reported to date in individuals with CEDS. The risk of lymphoma in people with <i>CASP8</i> pathogenic variants is not known, nor has the full spectrum of the disease been elucidated given the rarity of individuals with known pathogenic variants [<a class="bk_pop" href="#alps.REF.chun.2002.395">Chun et al 2002</a>, <a class="bk_pop" href="#alps.REF.oliveira.2013.722">Oliveira 2013</a>].</div></li><li class="half_rhythm"><div><b>Fas-associated via death <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> (FADD) deficiency</b> (OMIM <a href="http://omim.org/entry/613759" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">613759</a>). FADD deficiency is a rare, <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> primary immunodeficiency syndrome characterized by severe bacterial and viral infections, <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> heart defects, and recurrent episodes of fever, liver dysfunction, and seizures. Biochemical markers are consistent with ALPS, but the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals described to date do not have the characteristic clinical features of ALPS, including lymphadenopathy and splenomegaly [<a class="bk_pop" href="#alps.REF.bolze.2010.873">Bolze et al 2010</a>, <a class="bk_pop" href="#alps.REF.oliveira.2013.722">Oliveira 2013</a>, <a class="bk_pop" href="#alps.REF.savic.2015.502">Savic et al 2015</a>]. FADD deficiency is caused by <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>FADD</i>.</div></li><li class="half_rhythm"><div><b>Common variable immunodeficiency 9 (PRKCD</b>
<b>deficiency)</b> (OMIM <a href="http://omim.org/entry/615559" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">615559</a>). PRKCD deficiency is a rare, <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> primary immunodeficiency characterized by recurrent infections, lymphadenopathy, (hepato)splenomegaly, autoimmunity, and NK cell dysfunction. The full spectrum of the disease has not been elucidated given the small number of individuals with known pathogenic variants in <i>PRKCD</i> [<a class="bk_pop" href="#alps.REF.kuehn.2013.3117">Kuehn et al 2013</a>, <a class="bk_pop" href="#alps.REF.salzer.2013.3112">Salzer et al 2013</a>].</div></li><li class="half_rhythm"><div><b><i>CTLA4</i> <a class="def" href="/books/n/gene/glossary/def-item/haploinsufficiency/">haploinsufficiency</a> with autoimmune infiltration (CHAI)</b> (OMIM <a href="http://omim.org/entry/616100" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">616100</a>). CHAI is an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> immune dysregulation syndrome with incomplete <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> that is characterized by recurrent infections, autoimmune thrombocytopenias, CD4+ T-cell lymphopenia, B cell abnormalities, hypogammaglobulinemia, and abnormal lymphocytic infiltration of nonlymphoid organs such as brain, lungs and gastrointestinal tract. Additional features include diffuse lymphadenopathy, hepatosplenomegaly, and EBV-associated Hodgkin lymphoma [<a class="bk_pop" href="#alps.REF.kuehn.2014.1623">Kuehn et al 2014</a>, <a class="bk_pop" href="#alps.REF.schubert.2014.1410">Schubert et al 2014</a>]. CHAI is caused by <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> pathogenic <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> variants in <i>CTLA4</i>.</div></li></ul><p>Within the differential diagnosis for ALPS are other immunodeficiency disorders characterized or complicated by lymphoproliferation, autoimmune disease, and lymphoma. These include the following:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Common variable immune deficiency</b>
<b>(CVID)</b> has an estimated incidence of one in 50,000 and occurs equally in males and females. CVID is characterized by humoral immune deficiency with onset after age 24 months and usually in young adulthood, resulting in increased susceptibility to infections and diminished responses to protein and polysaccharide vaccines. Although multiple genes have been associated with CVID (see OMIM <a href="http://omim.org/phenotypicSeries/PS607594" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PS607594</a>), the genetic etiology of CVID in most <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals is currently unknown. From a clinical and immunologic standpoint, CVID can be roughly classified into two groups, depending on the presence or absence of mature B-cells in peripheral blood. Individuals with CVID with B-cells (but absent or decreased memory B-cells) are at an increased risk for autoimmune disease that often targets blood cells and for chronic lymphoproliferation including lymphadenopathy, splenomegaly, and lymphoma [<a class="bk_pop" href="#alps.REF.warnatz.2002.1544">Warnatz et al 2002</a>, <a class="bk_pop" href="#alps.REF.piqueras.2003.385">Piqueras et al 2003</a>]. CVID with present B cells should be regarded in the differential diagnosis of ALPS, while the variant characterized by low or absent B cells and generally low serum concentrations of immunoglobulins should not.</div><div class="half_rhythm">The overlap between ALPS and CVID is also illustrated by the report of two individuals with CVID who were found to have <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> pathogenic variants in <i>CASP8</i> [<a class="bk_pop" href="#alps.REF.chun.2002.395">Chun et al 2002</a>, <a class="bk_pop" href="#alps.REF.rensingehl.2010.357">Rensing-Ehl et al 2010</a>] and multiple individuals from unrelated families with CVID and enteropathy or autoimmunity who were found to have heterozygous pathogenic variants in <i>CTLA4</i> [<a class="bk_pop" href="#alps.REF.schubert.2014.1410">Schubert et al 2014</a>]. Biomarkers have also confirmed the overlap between ALPS and CVID [<a class="bk_pop" href="#alps.REF.roberts.2013.1531">Roberts et al 2013</a>].</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Hyper IgM (HIGM) syndrome.</b> Several non-<a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> forms of hyper IgM syndrome have now been identified. In varying degrees, they share features with the X-linked form (see <a href="/books/n/gene/xlhi/">X-Linked Hyper IgM Syndrome</a>), caused by pathogenic variants in <i>CD40LG</i>. Shared features include recurrent bacterial infections such as otitis media, sinusitis, and pneumonias. Autoimmune hematologic disorders including neutropenia, thrombocytopenia, and hemolytic anemia are also found. Other complications may include lymphomas and other malignancies as well as gastrointestinal complications. Serum concentration of IgM is elevated while other immunoglobulin levels are normal; specific antibody responses are defective. In contrast to HIGM1, T-cell function in ALPS is typically within normal limits, reflected in an absence of opportunistic infections.</div><div class="half_rhythm">HIGM2 (OMIM <a href="http://omim.org/entry/605258" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">605258</a>) is caused by pathogenic variants in <i>AICDA</i>, encoding single-stranded DNA cytosine deaminase. Inheritance is usually <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>, but in rare cases <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> [<a class="bk_pop" href="#alps.REF.revy.2000.565">Revy et al 2000</a>, <a class="bk_pop" href="#alps.REF.lee.2005.1881">Lee et al 2005</a>]. Recurrent bacterial, respiratory, and gastrointestinal infections are typical; opportunistic infections are rare. Lymphoid hyperplasia, seen in ALPS, has been reported in HIGM2 [<a class="bk_pop" href="#alps.REF.revy.2000.565">Revy et al 2000</a>, <a class="bk_pop" href="#alps.REF.lee.2005.1881">Lee et al 2005</a>]. <i>AICDA</i> pathogenic variants typically affect only B-cell differentiation.</div><div class="half_rhythm">HIGM3, HIGM4, and HIGM5 are other forms of non-<a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> hyper IgM syndrome (OMIM <a href="http://omim.org/phenotypicSeries/PS308230" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PS308230</a>). Their inclusion in the differential diagnosis of ALPS is less clear on the basis of known clinical presentation and inheritance pattern [<a class="bk_pop" href="#alps.REF.ferrari.2001.12614">Ferrari et al 2001</a>, <a class="bk_pop" href="#alps.REF.imai.2003.136">Imai et al 2003</a>].</div></li><li class="half_rhythm"><div class="half_rhythm"><a href="/books/n/gene/x-lpd/"><b>X-linked lymphoproliferative disease</b></a>
<b>(XLP)</b> caused by <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> pathogenic variants in <i>SH2D1A</i> is associated with an inappropriate immune response to Epstein-Barr virus (EBV) infection resulting in unusually <b>severe and often fatal infectious mononucleosis</b>, <b>dysgammaglobulinemia</b>; and/or <b>lymphoproliferative disorders</b> (typically of B-cell origin). Clinical manifestations of XLP vary, even among <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family members. The most common presentation is a near-fatal or fatal EBV infection associated with an unregulated and exaggerated immune response with widespread proliferation of cytotoxic T cells, EBV-infected B cells, and macrophages. Mortality is greater than 90%. In approximately one third of males with XLP, hypogammaglobulinemia of one or more immunoglobulin subclasses is diagnosed prior to EBV infection or in rare survivors of EBV infection. The prognosis for males with this <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> is more favorable if they are managed with regular intravenous immune globulin (IVIG) administration. Lymphomas or other lymphoproliferative diseases occur in approximately one third of males with XLP, some of whom have hypogammaglobulinemia or have survived an initial EBV infection. The lymphomas seen in individuals with XLP are typically high-grade B-cell lymphomas (non-Hodgkin type), are often extranodal, and particularly involve the intestine. Demonstration of defective T-cell receptor restimulation apoptosis in persons with XLP suggests that altered lymphocyte homeostasis affects disease pathogenesis as well [<a class="bk_pop" href="#alps.REF.snow.2008.34">Snow et al 2008</a>]. Allogeneic bone marrow transplantation (BMT) is the only curative therapy for XLP. Average life expectancy without curative BMT has been estimated at less than ten years. Note: XLP caused by pathogenic variants in <i>XIAP</i> has not been associated with lymphoproliferation or lymphoma to date.</div></li><li class="half_rhythm"><div class="half_rhythm"><a href="/books/n/gene/was/"><b>WAS-related disorders</b></a><b>,</b> which include Wiskott-Aldrich syndrome, <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> thrombocytopenia (XLT), and X-linked <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> neutropenia (XLN), are a spectrum of disorders of hematopoietic cells, with predominant defects of platelets and lymphocytes caused by mutation of <i>WAS</i>. <i>WAS</i>-related disorders usually present in infancy. Affected males have thrombocytopenia with intermittent mucosal bleeding, bloody diarrhea, and intermittent or chronic petechiae and purpura; eczema; and recurrent bacterial and viral infections, particularly recurrent ear infections. At least 40% of those who survive the early complications develop one or more autoimmune conditions including hemolytic anemia, immune thrombocytopenic purpura, immune-mediated neutropenia, arthritis, vasculitis of small and large vessels, and immune-mediated damage to the kidneys and liver. Individuals with a <i>WAS</i>-related disorder, particularly those who have been exposed to EBV, are at increased risk of developing lymphomas, which often occur in unusual, extranodal locations such as the brain, lung, or gastrointestinal tract. Males with XLT have thrombocytopenia with small platelets; other complications of Wiskott-Aldrich syndrome, including eczema and immune dysfunction, are mild or absent.</div></li><li class="half_rhythm"><div class="half_rhythm"><b><i>STAT3</i> <a class="def" href="/books/n/gene/glossary/def-item/gain-of-function/">gain-of-function</a> variants causing autoimmune disease</b> can result in clinical features such as lymphadenopathy, elevated &#x003b1;/&#x003b2;-DNT cells, and autoimmune cytopenia, resembling ALPS. Other findings include recurrent infections, short stature, and multiorgan autoimmunity. In contrast, <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> variants in <i>STAT3</i> are associated with immunodeficiency and hyper-IgE recurrent infection syndrome [<a class="bk_pop" href="#alps.REF.milner.2015.591">Milner et al 2015</a>].</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Lymphoma</b> without other manifestations of ALPS has been observed in families with ALPS-FAS. Thus, both B-cell and T-cell lymphoma should be considered in the differential diagnosis of ALPS [<a class="bk_pop" href="#alps.REF.van_der_werff_ten_bosch.1999.1045">van der Werff ten Bosch et al 1999</a>, <a class="bk_pop" href="#alps.REF.poppema.2004.423">Poppema et al 2004</a>].</div></li></ul></div><div id="alps.Management"><h2 id="_alps_Management_">Management</h2><div id="alps.Evaluations_Following_Initial_Diagn"><h3>Evaluations Following Initial Diagnosis</h3><p>To determine the presence and extent of disease and needs in an individual diagnosed with autoimmune lymphoproliferative syndrome (ALPS), the following evaluations are recommended:</p><ul><li class="half_rhythm"><div>Complete blood counts and flow cytometric immunophenotyping of lymphocytes, especially with regard to &#x003b1;/&#x003b2;-DNT cells, in combination with physical examination and imaging studies to assess lymphadenopathy and hepatosplenomegaly</div></li><li class="half_rhythm"><div>If significant lymphadenopathy is present, more extensive diagnostic procedures to detect lymphoma, especially if constitutional symptoms (e.g., fever, night sweats, weight loss) are present</div></li><li class="half_rhythm"><div>Measurement of autoantibodies to assess for autoimmunity</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="alps.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>In the absence of curative treatment, current management is focused on the following:</p><ul><li class="half_rhythm"><div>Monitoring for and treatment of lymphoproliferation, hypersplensim, and lymphomas</div></li><li class="half_rhythm"><div>Management of cytopenias and other autoimmune diseases [<a class="bk_pop" href="#alps.REF.madkaikar.2011.1">Madkaikar et al 2011</a>, <a class="bk_pop" href="#alps.REF.rao.2011.5741">Rao &#x00026; Oliveira 2011</a>, <a class="bk_pop" href="#alps.REF.teachey.2012.1">Teachey 2012</a>]</div></li></ul><p><b>Monitoring for and treatment of lymphoproliferation and hypersplenism</b></p><ul><li class="half_rhythm"><div>Manifestations of lymphoproliferation require close clinical observation, as well as serial CT and PET scans every two to three years.</div></li><li class="half_rhythm"><div>Biopsy is indicated whenever there is a clinical suspicion of lymphoma.</div></li><li class="half_rhythm"><div>Corticosteroids and immunosuppressive drugs do not decrease lymphadenopathy long term in individuals with ALPS, and are generally reserved for severe complications of lymphoproliferation (e.g., airway obstruction, significant hypersplenism associated with splenomegaly) and/or autoimmune manifestations.</div></li><li class="half_rhythm"><div>Experience with sirolimus suggests that it is the preferred agent in treating lymphoproliferation in a more sustained manner, including for maintenance of remission after initial treatment followed by a period of discontinued use [<a class="bk_pop" href="#alps.REF.teachey.2009.101">Teachey et al 2009</a>, <a class="bk_pop" href="#alps.REF.bride.2016.17">Bride et al 2016</a>]. However, sirolimus is not without side effects.</div></li><li class="half_rhythm"><div>In severe cases, more potent (lympho-depleting) agents may be required to sufficiently control lymphoproliferative manifestations. Agents include cyclophosphamide, antithymocyte globulin (ATG), and select monoclonal antibodies such as alemtuzumab (Campath<sup>&#x000ae;</sup>).</div></li></ul><p><b>Treatment of lymphoma</b> is according to conventional protocols. The presence of defective Fas-mediated apoptosis does not appear to hinder the response to chemotherapeutic agents or radiation.</p><p><b>Treatment of cytopenias and other autoimmune diseases</b></p><ul><li class="half_rhythm"><div>Autoimmune cytopenias are typically treated by immune suppression with corticosteroids as well as corticosteroid-sparing agents, if prolonged treatment of autoimmune cytopenias is required and/or in cases of refractory cytopenias.</div><ul><li class="half_rhythm"><div>Recent data from a multi-institutional study suggest that sirolimus should be considered as a first-line &#x02013; corticosteroid-sparing &#x02013; agent [<a class="bk_pop" href="#alps.REF.bride.2016.17">Bride et al 2016</a>]. Sirolimus requires monitoring for drug levels and toxic side effects.</div></li><li class="half_rhythm"><div>Mycophenolate mofetil (MMF) can be used in cases when a less immunosuppressive drug (e.g., compared with sirolimus) seems sufficient, as steroids are tapered. In addition, if drug level and toxic side effects cannot be adequately monitored, MMF could be used as a first-line agent.</div></li></ul></li><li class="half_rhythm"><div>Individuals with severe autoimmune hemolytic anemia may benefit from IVIG in combination with corticosteroids.</div></li><li class="half_rhythm"><div>Rituximab has been used successfully in the treatment of refractory cytopenias in ALPS. However, because of its immune toxicity, its use is generally avoided until other immunosuppression therapies have failed [<a class="bk_pop" href="#alps.REF.rao.2009.847">Rao et al 2009</a>, <a class="bk_pop" href="#alps.REF.rao.2011.5741">Rao &#x00026; Oliveira 2011</a>].</div></li><li class="half_rhythm"><div>Splenectomy is reserved as an option of last resort in the treatment of life-threatening refractory cytopenias and/or severe hypersplenia because of the high risk of recurrence of cytopenias and sepsis post-splenectomy in those with ALPS [<a class="bk_pop" href="#alps.REF.rao.2011.5741">Rao &#x00026; Oliveira 2011</a>, <a class="bk_pop" href="#alps.REF.price.2014.1989">Price et al 2014</a>]. Given the known risks associated with splenectomy, patients requiring this last-resort approach should be considered for curative bone marrow transplantation.</div></li><li class="half_rhythm"><div>Individuals with <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> chronic neutropenia may improve on low-dose G-CSF [<a class="bk_pop" href="#alps.REF.rao.2011.5741">Rao &#x00026; Oliveira 2011</a>]. In addition, use of a thrombopoietin (TPO) receptor agonist should be considered for isolated immune thrombocytopenia (ITP).</div></li></ul></div><div id="alps.Prevention_of_Primary_Manifestation"><h3>Prevention of Primary Manifestations</h3><p>Bone marrow (hematopoietic stem cell) transplantation (BMT/HSCT) is currently the only curative treatment for ALPS. Because of the risks associated with BMT, it has so far been performed mostly in individuals with ALPS with severe clinical phenotypes, such as those with <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> or <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> pathogenic variants in <i>FAS</i>, those with severe and/or refractory autoimmune cytopenias, those with lymphoma, and those who have developed complications from (often long-term) immunosuppressive therapy. It is likely, however, that individuals with undiagnosed forms of ALPS, including ALPS-FAS, have been transplanted.</p><p>Successful (reported) BMT in several individuals indicates that defective Fas-mediated apoptosis does not pose a barrier to this treatment option [<a class="bk_pop" href="#alps.REF.benkerrou.1997.2043">Benkerrou et al 1997</a>, <a class="bk_pop" href="#alps.REF.sleight.1998.375">Sleight et al 1998</a>, <a class="bk_pop" href="#alps.REF.dowdell.2010.5164">Dowdell et al 2010</a>].</p></div><div id="alps.Prevention_of_Secondary_Complicatio"><h3>Prevention of Secondary Complications</h3><p>Vaccinations pre-splenectomy (with consideration of post-splenectomy boost vaccinations) and penicillin prophylaxis are strongly recommended for individuals who undergo splenectomy.</p></div><div id="alps.Surveillance"><h3>Surveillance</h3><p>Clinical assessment, imaging, and laboratory studies outlined in <a href="#alps.Evaluations_Following_Initial_Diagn">Evaluations Following Initial Diagnosis</a> can be used in surveillance for manifestations of lymphoproliferation and autoimmunity.</p><p>Specialized imaging studies such as combined PET and CT scanning in combination with clinical and laboratory surveillance may be helpful in detection of malignant transformation, keeping in mind that PET/CT scanning is often abnormal in ALPS, such that distinguishing between "typical" ALPS findings and a new malignancy (lymphoma) can be difficult [<a class="bk_pop" href="#alps.REF.rao.2011.5741">Rao &#x00026; Oliveira 2011</a>]. Because of this, careful consideration of imaging modalities that expose the patient to radiation is warranted.</p></div><div id="alps.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p><b>Splenectomy</b> to control autoimmune cytopenias and/or massive splenomagaly is discouraged because it typically does not lead to permanent remission of autoimmunity and may be associated with an increased risk for infections. The two recent cohort studies reveal clear-cut consequences of splenectomy. In the French cohort, nine (30%) of 30 <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals who underwent splenectomy suffered 17 cases of severe invasive bacterial infection with four deaths after splenectomy; in the NIH cohort, 27 (41%) of 66 affected individuals suffered one or more episodes of sepsis with seven deaths. Of note: Anti-microbial prophylaxis and appropriate vaccinations did not prevent the majority of episodes of sepsis, although poor compliance was found to be a risk factor in the French cohort [<a class="bk_pop" href="#alps.REF.neven.2011.4798">Neven et al 2011</a>, <a class="bk_pop" href="#alps.REF.price.2014.1989">Price et al 2014</a>].</p><p>The use of over-the-counter medications such as aspirin and other nonsteroidal anti-inflammatory drugs should be discussed with a physician as some of these medications can interfere with platelet function.</p></div><div id="alps.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to perform <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> on relatives at risk for ALPS-FAS, ALPS-FASLG, or ALPS-CASP10 if the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</p><p>Relatives who have the family-specific <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> should:</p><ul><li class="half_rhythm"><div>Be advised of their increased risk for ALPS if the type and location of the ALPS-related <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is predicted to have a high <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> for clinical ALPS;</div></li><li class="half_rhythm"><div>Undergo ALPS-specific evaluations at initial diagnosis (e.g., enumeration of &#x003b1;/&#x003b2;-DNT cells, detection of autoantibodies, IL-10/soluble FasL measurement) (see <a href="#alps.Evaluations_Following_Initial_Diagn">Evaluations Following Initial Diagnosis</a>);</div></li><li class="half_rhythm"><div>Be advised that ALPS-specific evaluations or other assessments may need to be repeated at regular intervals, particularly if the family member is young and/or if new health-related issues consistent with ALPS or ALPS-related complications (e.g., lymphoma) become apparent (see <a href="#alps.Surveillance">Surveillance</a>).</div></li></ul><p>See <a href="#alps.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="alps.Pregnancy_Management"><h3>Pregnancy Management</h3><p>In addition to the risks and benefits to a woman with ALPS associated with treatment with corticosteroids, mycophenylate mofitil, or sirolimus during pregnancy, the potential teratogenic risks of these exposures to the fetus must also be weighed.</p><p>See <a href="http://www.mothertobaby.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">MotherToBaby</a> for further information on medication use during pregnancy.</p></div><div id="alps.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions.</p></div></div><div id="alps.Genetic_Counseling"><h2 id="_alps_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="alps.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Inheritance of ALPS-CASP10, most cases of ALPS-FAS, and some cases of ALPS-FASLG is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>. Inheritance of most cases of ALPS-FASLG and severe ALPS associated with <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>FAS</i> pathogenic variants is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>.</p><p>ALPS-FAS can also be the result of <a class="def" href="/books/n/gene/glossary/def-item/somatic-mosaicism/">somatic mosaicism</a>. Somatic pathogenic variants have not been reported in ALPS-FASLG or ALPS-CASP10 to date.</p></div><div id="alps.Risk_to_Family_Members__Autosomal_D"><h3>Risk to Family Members &#x02013; Autosomal Dominant ALPS</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Most individuals diagnosed with ALPS-FAS have a parent who has a <i>FAS</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. Individuals who are <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for a <i>FAS</i> pathogenic variant all have defective Fas-mediated apoptosis but may have no clinical findings of ALPS (see <a href="#alps.Penetrance">Penetrance</a>).</div></li><li class="half_rhythm"><div>An insufficient number of cases of ALPS-FASLG and ALPS-CASP10 are available to determine the likelihood that the <i>FASLG</i> or <i>CASP10</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> was inherited from a parent.</div></li><li class="half_rhythm"><div>A <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with ALPS-FAS, ALPS-FASLG, or ALPS-CASP10 may have the disorder as the result of a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. The proportion of cases caused by a <i>de novo</i>
<i>FAS</i> germline pathogenic variant is small (the proportion of cases caused by a <i>de novo FASLG</i> or <i>CASP10</i> is unknown).</div></li><li class="half_rhythm"><div>Recommendations for the evaluation of parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with a possible <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> (i.e., neither parent is known to be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> with ALPS) include <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> for the pathogenic variant identified in the proband.</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in the leukocyte DNA of either parent, possible explanations include a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> somatic or <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> pathogenic variant in the proband or <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> in a parent.</div></li><li class="half_rhythm"><div>Although most individuals diagnosed with ALPS have a parent with a <i>FAS</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the family history may appear to be negative because of reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> of the clinical symptoms of ALPS (as opposed to the nearly complete penetrance of the cellular <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> in individuals with a <i>FAS</i> pathogenic variant), failure to recognize the disorder in family members, early death of the parent before the onset of symptoms, or late onset of the disease in the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent. Therefore, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> is the most accurate means of determining the genetic status of at-risk individuals.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to the sibs of the proband depends on the genetic status of the proband's parents.</p><ul><li class="half_rhythm"><div>If a parent of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has a <i>FAS</i>, <i>FASLG</i>, or <i>CASP10</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, each sib has a 50% chance of inheriting the variant. The risk of developing ALPS-related complications, however, depends on the nature of the variant, as well as the presence of other as-yet incompletely understood genetic or environmental factors.</div></li><li class="half_rhythm"><div>If the <i>FAS</i>, <i>FASLG</i>, or <i>CASP10</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in the leukocyte DNA of either parent, the empiric <a class="def" href="/books/n/gene/glossary/def-item/recurrence-risk/">recurrence risk</a> to sibs is approximately 1% because of the theoretic possibility of parental <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Each child of an individual with ALPS-FAS, ALPS-FASLG, or ALPS-CASP10 has a 50% chance of inheriting the <i>FAS, FASLG</i>, or <i>CASP10</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div></li><li class="half_rhythm"><div>The risk to a child who has inherited the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> of developing ALPS-related complications depends on the nature of the pathogenic variant as well as the presence of other as-yet incompletely understood genetic or environmental factors (see <a href="#alps.Penetrance">Penetrance</a>).</div></li></ul><p><b>Other family members.</b> The risk to other family members depends on the genetic status of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents: if a parent has a <i>FAS</i>, <i>FASLG</i>, or <i>CASP10</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, his or her family members may have inherited the same variant and are potentially at some increased risk of developing ALPS-related complications.</p></div><div id="alps.Risk_to_Family_Members__Autosomal_R"><h3>Risk to Family Members &#x02013; Autosomal Recessive ALPS</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of a child with ALPS-FAS or ALPS-FASLG resulting from <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants are likely to be heterozygotes, in which case each parent would have one <i>FAS</i> or <i>FASLG</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div></li><li class="half_rhythm"><div>Heterozygotes may present with ALPS-related findings or may be clinically asymptomatic.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each sib of a child with ALPS-FAS or ALPS-FASLG resulting from <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants has:</div><ul><li class="half_rhythm"><div>An overall 75% chance of having one or two <i>FAS/FASLG</i> pathogenic variants;</div></li><li class="half_rhythm"><div>A 25% chance of inheriting two <i>FAS/FASLG</i> pathogenic variants, which would most likely result in a severe ALPS <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>;</div></li><li class="half_rhythm"><div>A 50% chance of inheriting a single <i>FAS/FASLG</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, which could result in clinical manifestations of ALPS;</div></li><li class="half_rhythm"><div>A 25% chance of inheriting one normal <i>FAS/FASLG</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> from each parent and having no clinical manifestations of ALPS.</div></li></ul></li><li class="half_rhythm"><div>Heterozygotes may present with ALPS-related symptoms or may be clinically asymptomatic.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Individuals with ALPS resulting from <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants are more likely to die at an early age and thus are not as likely to reproduce.</p><p><b>Other family members.</b> If a parent of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has an ALPS-related <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, his/her sibs are at a 50% risk of having the variant.</p></div><div id="alps.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#alps.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Testing of at-risk asymptomatic family members</b> for <i>FAS</i>, <i>FASLG</i>, or <i>CASP10</i> pathogenic variants is possible once the variant(s) are identified in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>. Although the factors that determine the <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> of clinical ALPS are not entirely understood, penetrance appears to be determined by the location and type of variant. Results of testing of at-risk asymptomatic family members can reduce morbidity and mortality through early diagnosis and treatment and may be helpful in predicting <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>.</p><p>Molecular genetic testing of asymptomatic individuals should in general be undertaken following thorough <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> and assessment of family-specific risks.</p><p><b>Considerations in families with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</b> When neither parent of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> condition has the pathogenic variant identified in the proband or clinical evidence of the disorder, the pathogenic variant is likely <i>de novo</i>. However, non-medical explanations including <a class="def" href="/books/n/gene/glossary/def-item/alternate-paternity/">alternate paternity</a> or maternity (e.g., with assisted reproduction) and undisclosed adoption could also be explored.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or at risk.</div></li><li class="half_rhythm"><div>Prior to pregnancy, <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> women should be advised about the teratogenic risks associated with medications used to treat ALPS.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="alps.Prenatal_Testing_and_Preimplantatio"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>FAS,</i>
<i>FASLG</i>, or <i>CASP10</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>(s) have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for ALPS are possible.</p></div></div><div id="alps.Resources"><h2 id="_alps_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>National Institute of Allergy and Infectious Diseases (NIAID)</b></div><div>NIAID Office of Communications and Government Relations</div><div>6610 Rockledge Drive</div><div>MSC 6612</div><div>Bethesda MD 20892-6612</div><div><b>Phone:</b> 866-284-4107 (toll-free); 301-496-5717; 800-877-8339 (toll-free TDD)</div><div><b>Fax:</b> 301-402-3573</div><div><b>Email:</b> ocpostoffice@niaid.nih.gov</div><div><a href="https://www.niaid.nih.gov/diseases-conditions/autoimmune-lymphoproliferative-syndrome-alps" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Autoimmune Lymphoproliferative Syndrome (ALPS)</a></div></li><li class="half_rhythm"><div><b>American Autoimmune Related Diseases Association, Inc. (AARDA)</b></div><div>22100 Gratiot Avenue</div><div>East Detroit MI 48021</div><div><b>Phone:</b> 800-598-4668 (toll-free); 586-776-3900</div><div><b>Fax:</b> 586-776-3903</div><div><b>Email:</b> aarda@aarda.org</div><div><a href="http://www.aarda.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.aarda.org</a></div></li><li class="half_rhythm"><div><b>Canadian Immunodeficiencies Patient Organization (CIPO)</b></div><div>362 Concession Road 12</div><div>RR #2</div><div>Hastings Ontario K0L 1Y0</div><div>Canada</div><div><b>Phone:</b> 877-262-2476 (toll-free)</div><div><b>Fax:</b> 866-942-7651 (toll-free)</div><div><b>Email:</b> info@cipo.ca</div><div><a href="http://cipo.ca" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.cipo.ca</a></div></li><li class="half_rhythm"><div><b>Jeffrey Modell Foundation/National Primary Immunodeficiency Resource Center</b></div><div>747 Third Avenue</div><div>New York NY 10017</div><div><b>Phone:</b> 866-463-6474 (toll-free); 212-819-0200</div><div><b>Fax:</b> 212-764-4180</div><div><b>Email:</b> info@jmfworld.org</div><div><a href="http://www.info4pi.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.info4pi.org</a></div></li><li class="half_rhythm"><div><b>European Society for Immunodeficiencies (ESID) Registry</b></div><div>Dr. Gerhard Kindle</div><div>University Medical Center Freiburg Centre of Chronic Immunodeficiency</div><div>Engesserstr. 4</div><div>79106 Freiburg </div><div>Germany</div><div><b>Phone:</b> 49-761-270-34450</div><div><b>Email:</b> esid-registry@uniklinik-freiburg.de</div><div><a href="http://esid.org/Working-Parties/Registry" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ESID Registry</a></div></li><li class="half_rhythm"><div><b>Primary Immunodeficiency Diseases Registry at USIDNET</b></div><div>40 West Chesapeake Avenue</div><div>Suite 308</div><div>Towson MD 21204-4803</div><div><b>Phone:</b> 866-939-7568</div><div><b>Fax:</b> 410-321-0293</div><div><b>Email:</b> contact@usidnet.org</div><div><a href="http://usidnet.org/usidnet-registry/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Primary Immunodeficiency Registry at USIDNET</a></div></li></ul></div><div id="alps.Molecular_Genetics"><h2 id="_alps_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="alps.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Autoimmune Lymphoproliferative Syndrome: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1108/table/alps.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__alps.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_alps.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_alps.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_alps.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_alps.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_alps.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_alps.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_alps.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/843" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>CASP10</i></a></td><td headers="hd_b_alps.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=843" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">2q33<wbr style="display:inline-block"></wbr>​.1</a></td><td headers="hd_b_alps.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q92851" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Caspase-10</a></td><td headers="hd_b_alps.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://research.cchmc.org/LOVD2/home.php?select_db=CASP10" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CCHMC - Human Genetics Mutation Database (CASP10)</a><br /><a href="http://structure.bmc.lu.se/idbase/CASP10base/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CASP10base: Mutation registry for Autoimmune lymphoproliferative syndrome, type II (ALPS2)</a></td><td headers="hd_b_alps.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=CASP10" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CASP10</a></td><td headers="hd_b_alps.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=CASP10[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CASP10</a></td></tr><tr><td headers="hd_b_alps.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/355" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>FAS</i></a></td><td headers="hd_b_alps.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=355" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">10q23<wbr style="display:inline-block"></wbr>​.31</a></td><td headers="hd_b_alps.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P25445" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Tumor necrosis factor receptor superfamily member 6</a></td><td headers="hd_b_alps.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://research.cchmc.org/LOVD2/home.php?select_db=FAS" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CCHMC - Human Genetics Mutation Database (FAS)</a><br /><a href="https://research.nhgri.nih.gov/ALPS/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Autoimmune Lymphoproliferative Syndrome Database (FAS)</a></td><td headers="hd_b_alps.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=FAS" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">FAS</a></td><td headers="hd_b_alps.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=FAS[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">FAS</a></td></tr><tr><td headers="hd_b_alps.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/356" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>FASLG</i></a></td><td headers="hd_b_alps.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=356" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">1q24<wbr style="display:inline-block"></wbr>​.3</a></td><td headers="hd_b_alps.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P48023" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Tumor necrosis factor ligand superfamily member 6</a></td><td headers="hd_b_alps.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://research.cchmc.org/LOVD2/home.php?select_db=FASLG" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CCHMC - Human Genetics Mutation Database (FASLG)</a><br /><a href="http://structure.bmc.lu.se/idbase/FASLGbase/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">FASLGbase: Mutation registry for Autoimmune lymphoproliferative syndrome, type 1B (ALPS1B) (previously known as TNFSF6base)</a></td><td headers="hd_b_alps.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=FASLG" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">FASLG</a></td><td headers="hd_b_alps.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=FASLG[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">FASLG</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="alps.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="alps.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Autoimmune Lymphoproliferative Syndrome (<a href="/omim/134637,134638,601762,601859,603909" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1108/table/alps.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__alps.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/134637" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">134637</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FAS CELL SURFACE DEATH RECEPTOR; FAS</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/134638" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">134638</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FAS LIGAND; FASLG</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/601762" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">601762</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CASPASE 10, APOPTOSIS-RELATED CYSTEINE PROTEASE; CASP10</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/601859" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">601859</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; ALPS</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/603909" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">603909</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME, TYPE IIA; ALPS2A</td></tr></tbody></table></div></div><div id="alps.Molecular_Pathogenesis"><h3>Molecular Pathogenesis</h3><p>Autoimmune lymphoproliferative syndrome (ALPS) can be considered a prototypic disorder of defective lymphocyte homeostasis [<a class="bk_pop" href="#alps.REF.sneller.1992.334">Sneller et al 1992</a>, <a class="bk_pop" href="#alps.REF.fisher.1995.935">Fisher et al 1995</a>, <a class="bk_pop" href="#alps.REF.rieuxlaucat.1995.1347">Rieux-Laucat et al 1995</a>]. Although it appears that the full clinical spectrum of ALPS may depend on the interplay of several pathogenic factors, defective activation-induced cell death (also known as apoptosis or cellular suicide) through the Fas/FasL pathway is central in the etiology of ALPS [<a class="bk_pop" href="#alps.REF.lenardo.1999.221">Lenardo et al 1999</a>]. (Note: <a class="bk_pop" href="#alps.REF.bleesing.2002.339">Bleesing [2002]</a>, Figure 1 diagrams this process; login or purchase required.)</p><div id="alps.CASP10"><h4><i>CASP10</i></h4><p><b>Gene structure.</b>
<i>CASP10</i> comprises 11 exons and spans approximately 48 kb [<a class="bk_pop" href="#alps.REF.hadano.2001.200">Hadano et al 2001</a>]. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1108/#alps.molgen.TA">Table A</a>, <b>Gene</b>. There are two <a class="def" href="/books/n/gene/glossary/def-item/isoforms/">isoforms</a> of <i>CASP10</i> transcripts. The <i>CASP10</i><sub>L</sub> isoform encodes an additional 43 amino acids at the end of the prodomain, but its C terminus is the same as the short <i>CASP10</i> isoform. The two isoforms are expressed equally.</p><p><b>Pathogenic variants.</b> To date, four <i>CASP10</i> pathogenic variants have been reported in individuals with ALPS [<a class="bk_pop" href="#alps.REF.wang.1999.47">Wang et al 1999</a>, <a class="bk_pop" href="#alps.REF.zhu.2006.284">Zhu et al 2006</a>, <a class="bk_pop" href="#alps.REF.cerutti.2007.28">Cerutti et al 2007</a>] (see <a class="figpopup" href="/books/NBK1108/table/alps.T.selected_casp10_pathogenic_varian/?report=objectonly" target="object" rid-figpopup="figalpsTselectedcasp10pathogenicvarian" rid-ob="figobalpsTselectedcasp10pathogenicvarian">Table 3</a>). Two <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants, p.Leu285Phe and p.Ile406Leu, were identified in one and two kindreds, respectively, with ALPS-CASP10 characterized by abnormal lymphocyte and dendritic cell homeostasis and immune regulatory defects [<a class="bk_pop" href="#alps.REF.wang.1999.47">Wang et al 1999</a>, <a class="bk_pop" href="#alps.REF.zhu.2006.284">Zhu et al 2006</a>].</p><p><a class="bk_pop" href="#alps.REF.cerutti.2007.28">Cerutti et al [2007]</a> described two patients who demonstrated coinheritance of both a <i>FAS</i> and a <i>CASP10</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. FAS expression and CASP10 activity were decreased in both patients. Additionally, a common variant of <i>CASP10</i> (p.Thr446Cys) originally thought to be benign [<a class="bk_pop" href="#alps.REF.wang.1999.47">Wang et al 1999</a>] has been associated with ALPS [<a class="bk_pop" href="#alps.REF.zhu.2006.284">Zhu et al 2006</a>].</p><div id="alps.T.selected_casp10_pathogenic_varian" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Selected <i>CASP10</i> Pathogenic Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1108/table/alps.T.selected_casp10_pathogenic_varian/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__alps.T.selected_casp10_pathogenic_varian_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_alps.T.selected_casp10_pathogenic_varian_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Variant Classification</th><th id="hd_h_alps.T.selected_casp10_pathogenic_varian_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change<br />(Alias&#x000a0;<sup>1</sup>)</th><th id="hd_h_alps.T.selected_casp10_pathogenic_varian_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change<br />(Alias&#x000a0;<sup>1</sup>)</th><th id="hd_h_alps.T.selected_casp10_pathogenic_varian_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference<br />Sequences</th></tr></thead><tbody><tr><td headers="hd_h_alps.T.selected_casp10_pathogenic_varian_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Benign</b></td><td headers="hd_h_alps.T.selected_casp10_pathogenic_varian_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1228G&#x0003e;A</td><td headers="hd_h_alps.T.selected_casp10_pathogenic_varian_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Val410Ile</td><td headers="hd_h_alps.T.selected_casp10_pathogenic_varian_1_1_1_4" rowspan="4" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/entrez/viewer.fcgi?val=NM_032977.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_032977<wbr style="display:inline-block"></wbr>​.3</a><br /><a href="/entrez/viewer.fcgi?val=NP_116759.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_116759<wbr style="display:inline-block"></wbr>​.2</a></td></tr><tr><td headers="hd_h_alps.T.selected_casp10_pathogenic_varian_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Pathogenic</b></td><td headers="hd_h_alps.T.selected_casp10_pathogenic_varian_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.853C&#x0003e;T<br />(724C&#x0003e;T)</td><td headers="hd_h_alps.T.selected_casp10_pathogenic_varian_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Leu285Phe<br />(Leu242Phe)</td></tr><tr><td headers="hd_h_alps.T.selected_casp10_pathogenic_varian_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.1216A&#x0003e;T<br />(1087A&#x0003e;T)</td><td headers="hd_h_alps.T.selected_casp10_pathogenic_varian_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ile406Leu<br />(Ile363Leu)</td></tr><tr><td headers="hd_h_alps.T.selected_casp10_pathogenic_varian_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.1337A&#x0003e;G&#x000a0;<sup>2</sup><br />(1208A&#x0003e;G)</td><td headers="hd_h_alps.T.selected_casp10_pathogenic_varian_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Tyr446Cys</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="alps.TF.3.1"><p class="no_margin">Variant designation that does not conform to current naming conventions</p></div></dd><dt>2. </dt><dd><div id="alps.TF.3.2"><p class="no_margin"><a class="bk_pop" href="#alps.REF.zhu.2006.284">Zhu et al [2006]</a></p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The physiologic function of caspase-10 is poorly understood. Gene transfection assays verified its function as a death-inducing caspase [<a class="bk_pop" href="#alps.REF.chaudhary.1997.821">Chaudhary et al 1997</a>, <a class="bk_pop" href="#alps.REF.pan.1997.815">Pan et al 1997</a>, <a class="bk_pop" href="#alps.REF.schneider.1997.831">Schneider et al 1997</a>, <a class="bk_pop" href="#alps.REF.vincenz.1997.6578">Vincenz &#x00026; Dixit 1997</a>]. Moreover, <a class="bk_pop" href="#alps.REF.wang.2001.13884">Wang et al [2001]</a> showed that caspase-10 can function independently of caspase-8 in initiating Fas and tumor necrosis factor-related apoptosis.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Pathogenic variants result in decreased caspase activity and dominantly interfere with death receptor-induced apoptosis, particularly with that stimulated by FasL and TRAIL.</p></div><div id="alps.FAS"><h4><i>FAS</i></h4><p><b>Gene structure.</b>
<i>FAS</i> comprises nine exons. Exons 1 and 2 encode a signal sequence that, upon trafficking of the Fas protein to the cell surface, is cleaved off. Exons 3, 4, and 5 encode three extracellular cysteine-rich domains (CRD). Exon 6 encodes the transmembrane <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a>. The intracellular domains of Fas are encoded by exons 7-9, with <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 9 representing the death domain that interacts with the intracellular, apoptosis-inducing signal transduction pathway [<a class="bk_pop" href="#alps.REF.jackson.1999.1002">Jackson et al 1999</a>]. Genomic DNA of <i>FAS</i> spans approximately 25 kb. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1108/#alps.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> To date, more than 130 pathogenic variants have been reported, including <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> and <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> variants, <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> defects, small deletions/insertions, gross deletions, and complex <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>/duplications. Many of these pathogenic variants are <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> alleles.</p><p>The discovery of individuals with ALPS with somatic pathogenic variants in <i>FAS</i> may offer new insights as the presence of pathogenic variants in some, but not all, lymphocyte subsets could allow dissection of the molecular mechanisms of ALPS in a manner that cannot be achieved in individuals with <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> variants in <i>FAS</i>.</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>FAS</i> encodes a 16-amino acid signal sequence, followed by a mature protein of 319 amino acids with a single transmembrane <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> and a molecular mass of approximately 36 kd.</p><p>The protein encoded by <i>FAS</i> is a member of the TNF-receptor superfamily and contains a death <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a>; it has been shown to play a central role in the physiologic regulation of programmed cell death. The interaction of Fas with its ligand allows the formation of a death-inducing signaling complex that includes Fas-associated death domain protein (FADD), caspase-8, and caspase-10. The autoproteolytic processing of the inductor caspases in the complex triggers a downstream effector caspase cascade, leading to apoptosis. Fas has also been shown to activate NF-kappa&#x003b2;, MAPK3/ERK1, and MAPK8/JNK, leading to the transduction of proliferating signals in normal diploid fibroblast and T cells.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Dominant-negative interference by abnormal Fas chains has been demonstrated for <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> pathogenic variants in the death <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a>, which lead to defective Fas-mediated apoptosis in many cases of ALPS-FAS [<a class="bk_pop" href="#alps.REF.jackson.1999.1002">Jackson et al 1999</a>, <a class="bk_pop" href="#alps.REF.martin.1999.4552">Martin et al 1999</a>]. Fas and FasL form homotrimers; therefore, normal Fas trimers (consisting of 3 normal proteins) occur in only one out of eight trimers, assuming equal amounts of mutated and wild type Fas protein [<a class="bk_pop" href="#alps.REF.fisher.1995.935">Fisher et al 1995</a>, <a class="bk_pop" href="#alps.REF.jackson.1999.1002">Jackson et al 1999</a>].</p><p>Extracellular <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> pathogenic variants affecting the FasL-binding <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> (CRD2 and CRD3) are also associated with <a class="def" href="/books/n/gene/glossary/def-item/dominant-negative/">dominant-negative</a> interference because Fas proteins self-associate into trimers prior to FasL interaction [<a class="bk_pop" href="#alps.REF.siegel.2000.2354">Siegel et al 2000</a>]. For other extracellular heterozygous pathogenic variants, including variants that affect the domain of the protein that regulates self-association into trimers, defective apoptosis can be explained by interference of truncated and/or soluble fragments of mutated Fas, or by <a class="def" href="/books/n/gene/glossary/def-item/haploinsufficiency/">haploinsufficiency</a>, in which the total amount of Fas generated is below a threshold needed for physiologic induction of apoptosis [<a class="bk_pop" href="#alps.REF.roesler.2005.1652">Roesler et al 2005</a>, <a class="bk_pop" href="#alps.REF.kuehn.2011.6035">Kuehn et al 2011</a>].</p><p>In individuals with <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> or <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> pathogenic variants, defective Fas-mediated apoptosis can be explained by loss of function [<a class="bk_pop" href="#alps.REF.van_der_burg.2000.336">van der Burg et al 2000</a>]. In contrast to those with heterozygous pathogenic variants, these individuals display absent or reduced surface expression of Fas on lymphocytes.</p></div><div id="alps.FASLG"><h4><i>FASLG</i></h4><p><b>Gene structure.</b>
<i>FASLG</i> (<i>FASL</i>) spans approximately 8 kb and comprises four exons. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1108/#alps.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> See <a class="figpopup" href="/books/NBK1108/table/alps.T.selected_faslg_pathogenic_variant/?report=objectonly" target="object" rid-figpopup="figalpsTselectedfaslgpathogenicvariant" rid-ob="figobalpsTselectedfaslgpathogenicvariant">Table 4</a>. To date, fewer than ten pathogenic alleles have been reported in <i>FASLG</i> in association with an ALPS <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a><i>.</i></p><div id="alps.T.selected_faslg_pathogenic_variant" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p>Selected <i>FASLG</i> Pathogenic Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1108/table/alps.T.selected_faslg_pathogenic_variant/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__alps.T.selected_faslg_pathogenic_variant_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA<br />Nucleotide<br />Change</th><th id="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Exon</th><th id="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Protein</th><th id="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Fas-Induced Apoptosis</th><th id="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_6" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AICD</th><th id="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_7" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Double-Negative T cells</th><th id="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_8" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">MOI</th><th id="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_9" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.203dupT&#x000a0;<sup>1</sup></td><td headers="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ala69fsTer138</td><td headers="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1</td><td headers="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Absent</td><td headers="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal</td><td headers="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">ND</td><td headers="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02191;</td><td headers="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_9" rowspan="7" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/entrez/viewer.fcgi?val=NM_000639.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000639<wbr style="display:inline-block"></wbr>​.1</a><br /><a href="/entrez/viewer.fcgi?val=NP_000630.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000630<wbr style="display:inline-block"></wbr>​.1</a></td></tr><tr><td headers="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.263delT&#x000a0;<sup>2</sup></td><td headers="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Phe87fsTer95</td><td headers="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1</td><td headers="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Absent</td><td headers="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal</td><td headers="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02193;</td><td headers="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02191;</td><td headers="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td></tr><tr><td headers="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.466A&#x0003e;G&#x000a0;<sup>3</sup></td><td headers="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg156Gly</td><td headers="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">4</td><td headers="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal</td><td headers="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Abnormal</td><td headers="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">ND</td><td headers="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal</td><td headers="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td></tr><tr><td headers="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.472_555del&#x000a0;<sup>4</sup></td><td headers="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Met158_Glu185del</td><td headers="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">4</td><td headers="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">ND</td><td headers="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">ND</td><td headers="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02193;</td><td headers="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal</td><td headers="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td></tr><tr><td headers="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.605G&#x0003e;C&#x000a0;<sup>5</sup></td><td headers="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Cys202Ser</td><td headers="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">4</td><td headers="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal</td><td headers="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal</td><td headers="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02193;</td><td headers="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02191;</td><td headers="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td></tr><tr><td headers="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.740C&#x0003e;A&#x000a0;<sup>6</sup></td><td headers="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ala247Glu</td><td headers="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">4</td><td headers="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal</td><td headers="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal</td><td headers="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02193;</td><td headers="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02191;</td><td headers="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td></tr><tr><td headers="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.829G&#x0003e;A&#x000a0;<sup>7</sup></td><td headers="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly277Ser</td><td headers="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">4</td><td headers="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal</td><td headers="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal</td><td headers="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02193;</td><td headers="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02191;</td><td headers="hd_h_alps.T.selected_faslg_pathogenic_variant_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>).</p></div></dd><dt></dt><dd><div><p class="no_margin">Note: All variants are associated with ALPS except p.Met158_Glu185del, which was observed in a patient with systemic lupus erythematosus and lymphadenopathy.</p></div></dd><dt></dt><dd><div><p class="no_margin">AD = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>; AICD = activation-induced cell death; AR = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>; MOI = <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a>; ND = not determined; &#x02191; = increased; &#x02193; = diminished</p></div></dd><dt>1. </dt><dd><div id="alps.TF.4.1"><p class="no_margin"><a class="bk_pop" href="#alps.REF.nabhani.2014.231">Nabhani et al [2014]</a></p></div></dd><dt>2. </dt><dd><div id="alps.TF.4.2"><p class="no_margin"><a class="bk_pop" href="#alps.REF.mageruschatinet.2013.486">Magerus-Chatinet et al [2013]</a></p></div></dd><dt>3. </dt><dd><div id="alps.TF.4.3"><p class="no_margin"><a class="bk_pop" href="#alps.REF.bi.2007.41">Bi et al [2007]</a></p></div></dd><dt>4. </dt><dd><div id="alps.TF.4.4"><p class="no_margin"><a class="bk_pop" href="#alps.REF.wu.1996.1107">Wu et al [1996]</a></p></div></dd><dt>5. </dt><dd><div id="alps.TF.4.5"><p class="no_margin"><a class="bk_pop" href="#alps.REF.ruizgarc_a.2015.603">Ruiz-Garc&#x000ed;a et al [2015]</a></p></div></dd><dt>6. </dt><dd><div id="alps.TF.4.6"><p class="no_margin">This patient developed peripheral T-cell lymphoma [<a class="bk_pop" href="#alps.REF.delrey.2006.1306">Del-Rey et al 2006</a>].</p></div></dd><dt>7. </dt><dd><div id="alps.TF.4.7"><p class="no_margin">Observed in two <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> sibs [<a class="bk_pop" href="#alps.REF.sobh.2016.324">Sobh et al 2016</a>]</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The <i>FASLG</i> <a class="def" href="/books/n/gene/glossary/def-item/cdna/">cDNA</a> encodes a protein of 281 amino acids. Fas ligand (FasL) is a type II transmembrane protein that belongs to the tumor necrosis factor family. It is expressed in activated splenocytes and thymocytes, consistent with its involvement in T cell-mediated cytotoxicity and in several non-lymphoid tissues (e.g., testis, liver, lung, ovary, heart), where its function is unclear.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The individual with the <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variant (p.Ala247Glu) showed decreased Fas-mediated cell death and Fas-dependent cytotoxicity [<a class="bk_pop" href="#alps.REF.delrey.2006.1306">Del-Rey et al 2006</a>]. The <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> p.Arg156Gly <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> affects the extracellular Fas-binding region of FASL. The variant produces a dominant interfering FasL protein that binds to wild type FasL, preventing Fas-mediated apoptosis [<a class="bk_pop" href="#alps.REF.bi.2007.41">Bi et al 2007</a>].</p></div></div></div><div id="alps.References"><h2 id="_alps_References_">References</h2><div id="alps.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="alps.REF.benkerrou.1997.2043">Benkerrou M, Le Deist F, de Villartay JP, Caillat-Zucman S, Rieux-Laucat F, Jabado N, Cavazzana-Calvo M, Fischer A. Correction of Fas (CD95) deficiency by haploidentical bone marrow transplantation. <span><span class="ref-journal">Eur J Immunol. </span>1997;<span class="ref-vol">27</span>:2043–7.</span> [<a href="/pubmed/9295043" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9295043</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.bi.2007.41">Bi LL, Pan G, Atkinson TP, Zheng L, Dale JK, Makris C, Reddy V, McDonald JM, Siegel RM, Puck JM, Lenardo MJ, Straus SE. Dominant inhibition of Fas ligand-mediated apoptosis due to a heterozygous mutation associated with autoimmune lymphoproliferative syndrome type Ib. <span><span class="ref-journal">BMC Med Genet. </span>2007;<span class="ref-vol">8</span>:41.</span> [<a href="/pmc/articles/PMC1931585/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1931585</span></a>] [<a href="/pubmed/17605793" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17605793</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.bleesing.2003.265">Bleesing JJ. Autoimmune lymphoproliferative syndrome (ALPS). <span><span class="ref-journal">Curr Pharm Des. </span>2003;<span class="ref-vol">9</span>:265–78.</span> [<a href="/pubmed/12570831" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12570831</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.bleesing.2005.571">Bleesing JJ. Sorting out the causes of ALPS. <span><span class="ref-journal">J Pediatr. </span>2005;<span class="ref-vol">147</span>:571–4.</span> [<a href="/pubmed/16291343" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16291343</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.bleesing.2001.2466">Bleesing JJ, Brown MR, Straus SE, Dale JK, Siegel RM, Johnson M, Lenardo MJ, Puck JM, Fleisher TA. Immunophenotypic profiles in families with autoimmune lymphoproliferative syndrome. <span><span class="ref-journal">Blood. </span>2001;<span class="ref-vol">98</span>:2466–73.</span> [<a href="/pubmed/11588044" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11588044</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.bleesing.2002.339">Bleesing JJH. Autoimmune lymphoproliferative syndrome: a genetic disorder of abnormal lymphocyte apoptosis. <span><span class="ref-journal">Immunol Allergy Clin North Am. </span>2002;<span class="ref-vol">22</span>:339–55.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.boggio.2014.1178">Boggio E, Clemente N, Mondino A, Cappellano G, Orilieri E, Gigliotti CL, Toth E, Ramenghi U, Dianzani U, Chiocchetti A. IL-17 protects T cells from apoptosis and contributes to development of ALPS-like phenotypes. <span><span class="ref-journal">Blood. </span>2014;<span class="ref-vol">123</span>:1178–86.</span> [<a href="/pubmed/24363402" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24363402</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.bolze.2010.873">Bolze A, Byun M, McDonald D, Morgan NV, Abhyankar A, Premkumar L, Puel A, Bacon CM, Rieux-Laucat F, Pang K, Britland A, Abel L, Cant A, Maher ER, Riedl SJ, Hambleton S, Casanova JL. Whole-exome-sequencing-based discovery of human FADD deficiency. <span><span class="ref-journal">Am J Hum Genet. </span>2010;<span class="ref-vol">87</span>:873–81.</span> [<a href="/pmc/articles/PMC2997374/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2997374</span></a>] [<a href="/pubmed/21109225" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21109225</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.bowen.2012.490">Bowen RA, Dowdell KC, Dale JK, Drake SK, Fleisher TA, Hortin GL, Remaley AT, Nexo E, Rao VK. Elevated vitamin B<sub>12</sub> levels in autoimmune lymphoproliferative syndrome attributable to elevated haptocorrin in lymphocytes. <span><span class="ref-journal">Clin Biochem. </span>2012;<span class="ref-vol">45</span>:490–2.</span> [<a href="/pmc/articles/PMC3307947/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3307947</span></a>] [<a href="/pubmed/22306884" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22306884</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.bride.2016.17">Bride KL, Vincent T, Smith-Whitley K, Lambert MP, Bleesing JJ, Seif AE, Manno CS, Casper J, Grupp SA, Teachey DT. Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. <span><span class="ref-journal">Blood. </span>2016;<span class="ref-vol">127</span>:17–28.</span> [<a href="/pmc/articles/PMC4705607/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4705607</span></a>] [<a href="/pubmed/26504182" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26504182</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.caminha.2010.946">Caminha I, Fleisher TA, Hornung RL, Dale JK, Niemela JE, Price S, Davis J, Perkins K, Dowdell KC, Brown MR, Rao VK, Oliveira JB. Using biomarkers to predict the presence of FAS mutations in patients with features of the autoimmune lymphoproliferative syndrome. <span><span class="ref-journal">J Allergy Clin Immunol. </span>2010;<span class="ref-vol">125</span>:946–9.e6.</span> [<a href="/pmc/articles/PMC3412519/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3412519</span></a>] [<a href="/pubmed/20227752" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20227752</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.carter.2000.943">Carter LB, Procter JL, Dale JK, Straus SE, Cantilena CC. Description of serologic features in autoimmune lymphoproliferative syndrome. <span><span class="ref-journal">Transfusion. </span>2000;<span class="ref-vol">40</span>:943–8.</span> [<a href="/pubmed/10960521" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10960521</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.cerutti.2007.28">Cerutti E, Campagnoli MF, Ferretti M, Garelli E, Crescenzio N, Rosolen A, Chiocchetti A, Lenardo MJ, Ramenghi U, Dianzani U. Co-inherited mutations of Fas and caspase-10 in development of the autoimmune lymphoproliferative syndrome. <span><span class="ref-journal">BMC Immunol. </span>2007;<span class="ref-vol">8</span>:28.</span> [<a href="/pmc/articles/PMC2211507/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2211507</span></a>] [<a href="/pubmed/17999750" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17999750</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.chaudhary.1997.821">Chaudhary PM, Eby M, Jasmin A, Bookwalter A, Murray J, Hood L. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. <span><span class="ref-journal">Immunity. </span>1997;<span class="ref-vol">7</span>:821–30.</span> [<a href="/pubmed/9430227" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9430227</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.chun.2002.395">Chun HJ, Zheng L, Ahmad M, Wang J, Speirs CK, Siegel RM, Dale JK, Puck J, Davis J, Hall CG, Skoda-Smith S, Atkinson TP, Straus SE, Lenardo MJ. Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency. <span><span class="ref-journal">Nature. </span>2002;<span class="ref-vol">419</span>:395–9.</span> [<a href="/pubmed/12353035" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12353035</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.delrey.2006.1306">Del-Rey M, Ruiz-Contreras J, Bosque A, Calleja S, Gomez-Rial J, Roldan E, Morales P, Serrano A, Anel A, Paz-Artal E, Allende LM. A homozygous Fas ligand gene mutation in a patient causes a new type of autoimmune lymphoproliferative syndrome. <span><span class="ref-journal">Blood. </span>2006;<span class="ref-vol">108</span>:1306–12.</span> [<a href="/pubmed/16627752" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16627752</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.dowdell.2010.5164">Dowdell KC, Niemela JE, Price S, Davis J, Hornung RL, Oliveira JB, Puck JM, Jaffe ES, Pittaluga S, Cohen JI, Fleisher TA, Rao VK. Somatic FAS mutations are common in patients with genetically undefined autoimmune lymphoproliferative syndrome. <span><span class="ref-journal">Blood. </span>2010;<span class="ref-vol">115</span>:5164–9.</span> [<a href="/pmc/articles/PMC2892951/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2892951</span></a>] [<a href="/pubmed/20360470" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20360470</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.ferrari.2001.12614">Ferrari S, Giliani S, Insalaco A, Al-Ghonaium A, Soresina AR, Loubser M, Avanzini MA, Marconi M, Badolato R, Ugazio AG, Levy Y, Catalan N, Durandy A, Tbakhi A, Notarangelo LD, Plebani A. Mutations of CD40 gene cause an autosomal recessive form of immunodeficiency with hyper IgM. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2001;<span class="ref-vol">98</span>:12614–9.</span> [<a href="/pmc/articles/PMC60102/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC60102</span></a>] [<a href="/pubmed/11675497" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11675497</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.fisher.1995.935">Fisher GH, Rosenberg FJ, Straus SE, Dale JK, Middleton LA, Lin AY, Strober W, Lenardo MJ, Puck JM. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. <span><span class="ref-journal">Cell. </span>1995;<span class="ref-vol">81</span>:935–46.</span> [<a href="/pubmed/7540117" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7540117</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.hadano.2001.200">Hadano S, Yanagisawa Y, Skaug J, Fichter K, Nasir J, Martindale D, Koop BF, Scherer SW, Nicholson DW, Rouleau GA, Ikeda J, Hayden MR. Cloning and characterization of three novel genes, ALS2CR1, ALS2CR2, and ALS2CR3, in the juvenile amyotrophic lateral sclerosis (ALS2) critical region at chromosome 2q33-q34: candidate genes for ALS2. <span><span class="ref-journal">Genomics. </span>2001;<span class="ref-vol">71</span>:200–13.</span> [<a href="/pubmed/11161814" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11161814</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.hauck.2013.61">Hauck F, Magerus-Chatinet A, Vicca S, Rensing-Ehl A, Roesen-Wolff A, Roesler J, Rieux-Laucat F. Somatic loss of heterozygosity, but not haploinsufficiency alone, leads to full-blown autoimmune lymphoproliferative syndrome in 1 of 12 family members with FAS start codon mutation. <span><span class="ref-journal">Clin Immunol. </span>2013;<span class="ref-vol">147</span>:61–8.</span> [<a href="/pubmed/23524443" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23524443</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.holzelova.2004.1409">Holzelova E, Vonarbourg C, Stolzenberg MC, Arkwright PD, Selz F, Prieur AM, Blanche S, Bartunkova J, Vilmer E, Fischer A, Le Deist F, Rieux-Laucat F. Autoimmune lymphoproliferative syndrome with somatic Fas mutations. <span><span class="ref-journal">N Engl J Med. </span>2004;<span class="ref-vol">351</span>:1409–18.</span> [<a href="/pubmed/15459302" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15459302</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.houston.2004.321">Houston A, O'Connell J. The Fas signalling pathway and its role in the pathogenesis of cancer. <span><span class="ref-journal">Curr Opin Pharmacol. </span>2004;<span class="ref-vol">4</span>:321–6.</span> [<a href="/pubmed/15251123" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15251123</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.imai.2003.136">Imai K, Catalan N, Plebani A, Mar&#x000f3;di L, Sanal O, Kumaki S, Nagendran V, Wood P, Glastre C, Sarrot-Reynauld F, Hermine O, Forveille M, Revy P, Fischer A, Durandy A. Hyper-IgM syndrome type 4 with a B lymphocyte-intrinsic selective deficiency in Ig class-switch recombination. <span><span class="ref-journal">J Clin Invest. </span>2003;<span class="ref-vol">112</span>:136–42.</span> [<a href="/pmc/articles/PMC162294/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC162294</span></a>] [<a href="/pubmed/12840068" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12840068</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.infante.1998.629">Infante AJ, Britton HA, DeNapoli T, Middelton LA, Lenardo MJ, Jackson CE, Wang J, Fleisher T, Straus SE, Puck JM. The clinical spectrum in a large kindred with autoimmune lymphoproliferative syndrome caused by a Fas mutation that impairs lymphocyte apoptosis. <span><span class="ref-journal">J Pediatr. </span>1998;<span class="ref-vol">133</span>:629–33.</span> [<a href="/pubmed/9821419" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9821419</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.jackson.1999.1002">Jackson CE, Fischer RE, Hsu AP, Anderson SM, Choi Y, Wang J, Dale JK, Fleisher TA, Middelton LA, Sneller MC, Lenardo MJ, Straus SE, Puck JM. Autoimmune lymphoproliferative syndrome with defective Fas: genotype influences penetrance. <span><span class="ref-journal">Am J Hum Genet. </span>1999;<span class="ref-vol">64</span>:1002–14.</span> [<a href="/pmc/articles/PMC1377824/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1377824</span></a>] [<a href="/pubmed/10090885" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10090885</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.kanegane.2003.454">Kanegane H, Vilela MM, Wang Y, Futatani T, Matsukura H, Miyawaki T. Autoimmune lymphoproliferative syndrome presenting with glomerulonephritis. <span><span class="ref-journal">Pediatr Nephrol. </span>2003;<span class="ref-vol">18</span>:454–6.</span> [<a href="/pubmed/12736807" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12736807</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.kasahara.1998.195">Kasahara Y, Wada T, Niida Y, Yachie A, Seki H, Ishida Y, Sakai T, Koizumi F, Koizumi S, Miyawaki T, Taniguchi N. Novel Fas (CD95/APO-1) mutations in infants with a lymphoproliferative disorder. <span><span class="ref-journal">Int Immunol. </span>1998;<span class="ref-vol">10</span>:195–202.</span> [<a href="/pubmed/9533447" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9533447</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.kuehn.2011.6035">Kuehn HS, Caminha I, Niemela JE, Rao VK, Davis J, Fleisher TA, Oliveira JB. FAS haploinsufficiency is a common disease mechanism in the human autoimmune lymphoproliferative syndrome. <span><span class="ref-journal">J Immunol. </span>2011;<span class="ref-vol">186</span>:6035–43.</span> [<a href="/pmc/articles/PMC3725553/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3725553</span></a>] [<a href="/pubmed/21490157" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21490157</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.kuehn.2013.3117">Kuehn HS, Niemela JE, Rangel-Santos A, Zhang M, Pittaluga S, Stoddard JL, Hussey AA, Evbuomwan MO, Priel DA, Kuhns DB, Park CL, Fleisher TA, Uzel G, Oliveira JB. Loss-of-function of the protein kinase C &#x003b4; (PKC&#x003b4;) causes a B-cell lymphoproliferative syndrome in humans. <span><span class="ref-journal">Blood. </span>2013;<span class="ref-vol">121</span>:3117–25.</span> [<a href="/pmc/articles/PMC3630827/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3630827</span></a>] [<a href="/pubmed/23430113" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23430113</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.kuehn.2014.1623">Kuehn HS, Ouyang W, Lo B, Deenick EK, Niemela JE, Avery DT, Schickel JN, Tran DQ, Stoddard J, Zhang Y, Frucht DM, Dumitriu B, Scheinberg P, Folio LR, Frein CA, Price S, Koh C, Heller T, Seroogy CM, Huttenlocher A, Rao VK, Su HC, Kleiner D, Notarangelo LD, Rampertaap Y, Olivier KN, McElwee J, Hughes J, Pittaluga S, Oliveira JB, Meffre E, Fleisher TA, Holland SM, Lenardo MJ, Tangye SG, Uzel G. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. <span><span class="ref-journal">Science. </span>2014;<span class="ref-vol">345</span>:1623–7.</span> [<a href="/pmc/articles/PMC4371526/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4371526</span></a>] [<a href="/pubmed/25213377" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25213377</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.lanzarotti.2014.1960">Lanzarotti N, Bruneau J, Trinquand A, Stolzenberg MC, Neven B, Fregeac J, Levy E, Jeremiah N, Suarez F, Mahlaoui N, Fischer A, Magerus-Chatinet A, Cav&#x000e9; H, Rieux-Laucat F. RAS-associated lymphoproliferative disease evolves into severe juvenile myelo-monocytic leukemia. <span><span class="ref-journal">Blood. </span>2014;<span class="ref-vol">123</span>:1960–3.</span> [<a href="/pubmed/24652966" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24652966</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.le_deist.2004">Le Deist F. Autoimmune lymphoproliferative syndrome. Orphanet Encyclopedia. 2004.</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.le_deist.1996.719">Le Deist F, Emile JF, Rieux-Laucat F, Benkerrou M, Roberts I, Brousse N, Fischer A. Clinical, immunological, and pathological consequences of Fas-deficient conditions. <span><span class="ref-journal">Lancet. </span>1996;<span class="ref-vol">348</span>:719–23.</span> [<a href="/pubmed/8806292" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8806292</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.lee.2005.1881">Lee WI, Torgerson TR, Schumacher MJ, Yel L, Zhu Q, Ochs HD. Molecular analysis of a large cohort of patients with the hyper immunoglobulin M (IgM) syndrome. <span><span class="ref-journal">Blood. </span>2005;<span class="ref-vol">105</span>:1881–90.</span> [<a href="/pubmed/15358621" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15358621</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.lenardo.1999.221">Lenardo M, Chan KM, Hornung F, McFarland H, Siegel R, Wang J, Zheng L. Mature T lymphocyte apoptosis--immune regulation in a dynamic and unpredictable antigenic environment. <span><span class="ref-journal">Annu Rev Immunol. </span>1999;<span class="ref-vol">17</span>:221–53.</span> [<a href="/pubmed/10358758" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10358758</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.lim.1998.1541">Lim MS, Straus SE, Dale JK, Fleisher TA, Stetler-Stevenson M, Strober W, Sneller MC, Puck JM, Lenardo MJ, Elenitoba-Johnson KS, Lin AY, Raffeld M, Jaffe ES. Pathological findings in human autoimmune lymphoproliferative syndrome. <span><span class="ref-journal">Am J Pathol. </span>1998;<span class="ref-vol">153</span>:1541–50.</span> [<a href="/pmc/articles/PMC1853411/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1853411</span></a>] [<a href="/pubmed/9811346" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9811346</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.madkaikar.2011.1">Madkaikar M, Mhatre S, Gupta M, Ghosh K. Advances in autoimmune lymphoproliferative syndromes. <span><span class="ref-journal">Eur J Haematol. </span>2011;<span class="ref-vol">87</span>:1–9.</span> [<a href="/pubmed/21447005" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21447005</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.mageruschatinet.2011.106">Magerus-Chatinet A, Neven B, Stolzenberg MC, Daussy C, Arkwright PD, Lanzarotti N, Schaffner C, Cluet-Dennetiere S, Haerynck F, Michel G, Bole-Feysot C, Zarhrate M, Radford-Weiss I, Romana SP, Picard C, Fischer A, Rieux-Laucat F. Onset of autoimmune lymphoproliferative syndrome (ALPS) in humans as a consequence of genetic defect accumulation. <span><span class="ref-journal">J Clin Invest. </span>2011;<span class="ref-vol">121</span>:106–12.</span> [<a href="/pmc/articles/PMC3007148/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3007148</span></a>] [<a href="/pubmed/21183795" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21183795</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.mageruschatinet.2013.486">Magerus-Chatinet A, Stolzenberg MC, Lanzarotti N, Neven B, Daussy C, Picard C, Neveux N, Desai M, Rao M, Ghosh K, Madkaikar M, Fischer A, Rieux-Laucat F. Autoimmune lymphoproliferative syndrome caused by a homozygous null FAS ligand (FASLG) mutation. <span><span class="ref-journal">J Allergy Clin Immunol. </span>2013;<span class="ref-vol">131</span>:486–90.</span> [<a href="/pmc/articles/PMC3824280/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3824280</span></a>] [<a href="/pubmed/22857792" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22857792</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.mageruschatinet.2009.3027">Magerus-Chatinet A, Stolzenberg MC, Loffredo MS, Neven B, Schaffner C, Ducrot N, Arkwright PD, Bader-Meunier B, Barbot J, Blanche S, Casanova JL, Debr&#x000e9; M, Ferster A, Fieschi C, Florkin B, Galambrun C, Hermine O, Lambotte O, Solary E, Thomas C, Le Deist F, Picard C, Fischer A, Rieux-Laucat F. FAS-L, IL-10, and double-negative CD4- CD8- TCR alpha/beta+ T cells are reliable markers of autoimmune lymphoproliferative syndrome (ALPS) associated with FAS loss of function. <span><span class="ref-journal">Blood. </span>2009;<span class="ref-vol">113</span>:3027–30.</span> [<a href="/pubmed/19176318" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19176318</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.maric.2005.903">Maric I, Pittaluga S, Dale JK, Niemela JE, Delsol G, Diment J, Rosai J, Raffeld M, Puck JM, Straus SE, Jaffe ES. Histologic features of sinus histiocytosis with massive lymphadenopathy in patients with autoimmune lymphoproliferative syndrome. <span><span class="ref-journal">Am J Surg Pathol. </span>2005;<span class="ref-vol">29</span>:903–11.</span> [<a href="/pubmed/15958855" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15958855</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.martin.1999.4552">Martin DA, Zheng L, Siegel RM, Huang B, Fisher GH, Wang J, Jackson CE, Puck JM, Dale J, Straus SE, Peter ME, Krammer PH, Fesik S, Lenardo MJ. Defective CD95/APO-1/Fas signal complex formation in the human autoimmune lymphoproliferative syndrome, type Ia. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>1999;<span class="ref-vol">96</span>:4552–7.</span> [<a href="/pmc/articles/PMC16370/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC16370</span></a>] [<a href="/pubmed/10200300" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10200300</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.milner.2015.591">Milner JD, Vogel TP, Forbes L, Ma CA, Stray-Pedersen A, Niemela JE, Lyons JJ, Engelhardt KR, Zhang Y, Topcagic N, Roberson ED, Matthews H, Verbsky JW, Dasu T, Vargas-Hernandez A, Varghese N, McClain KL, Karam LB, Nahmod K, Makedonas G, Mace EM, Sorte HS, Perminow G, Rao VK, O'Connell MP, Price S, Su HC, Butrick M, McElwee J, Hughes JD, Willet J, Swan D, Xu Y, Santibanez-Koref M, Slowik V, Dinwiddie DL, Ciaccio CE, Saunders CJ, Septer S, Kingsmore SF, White AJ, Cant AJ, Hambleton S, Cooper MA. Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations. <span><span class="ref-journal">Blood. </span>2015;<span class="ref-vol">125</span>:591–9.</span> [<a href="/pmc/articles/PMC4304103/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4304103</span></a>] [<a href="/pubmed/25359994" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25359994</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.m_schen.2002.75">M&#x000fc;schen M, Rajewsky K, Kr&#x000f6;nke M, K&#x000fc;ppers R. The origin of CD95-gene mutations in B-cell lymphoma. <span><span class="ref-journal">Trends Immunol. </span>2002;<span class="ref-vol">23</span>:75–80.</span> [<a href="/pubmed/11929130" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11929130</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.nabhani.2014.231">Nabhani S, H&#x000f6;nscheid A, Oommen PT, Fleckenstein B, Schaper J, Kuhlen M, Laws HJ, Borkhardt A, Fischer U. A novel homozygous Fas ligand mutation leads to early protein truncation, abrogation of death receptor and reverse signaling and a severe form of the autoimmune lymphoproliferative syndrome. <span><span class="ref-journal">Clin Immunol. </span>2014;<span class="ref-vol">155</span>:231–7.</span> [<a href="/pubmed/25451160" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25451160</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.neven.2014.1597">Neven B, Bruneau J, Stolzenberg MC, Meyts I, Magerus-Chatinet A, Moens L, Lanzarotti N, Weller S, Amiranoff D, Florkin B, Bader-Meunier B, Leverger G, Ferster A, Chantrain C, Blanche S, Picard C, Molina TJ, Brousse N, Durandy A, Rizzi M, Bossuyt X, Fischer A, Rieux-Laucat F. Defective anti-polysaccharide response and splenic marginal zone disorganization in ALPS patients. <span><span class="ref-journal">Blood. </span>2014;<span class="ref-vol">124</span>:1597–609.</span> [<a href="/pubmed/24970930" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24970930</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.neven.2011.4798">Neven B, Magerus-Chatinet A, Florkin B, Gobert D, Lambotte O, De Somer L, Lanzarotti N, Stolzenberg MC, Bader-Meunier B, Aladjidi N, Chantrain C, Bertrand Y, Jeziorski E, Leverger G, Michel G, Suarez F, Oksenhendler E, Hermine O, Blanche S, Picard C, Fischer A, Rieux-Laucat F. A survey of 90 patients with autoimmune lymphoproliferative syndrome related to TNFRSF6 mutation. <span><span class="ref-journal">Blood. </span>2011;<span class="ref-vol">118</span>:4798–807.</span> [<a href="/pubmed/21885602" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21885602</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.niemela.2011.2883">Niemela JE, Lu L, Fleisher TA, Davis J, Caminha I, Natter M, Beer LA, Dowdell KC, Pittaluga S, Raffeld M, Rao VK, Oliveira JB. Somatic KRAS mutations associated with a human nonmalignant syndrome of autoimmunity and abnormal leukocyte homeostasis. <span><span class="ref-journal">Blood. </span>2011;<span class="ref-vol">117</span>:2883–6.</span> [<a href="/pmc/articles/PMC3062298/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3062298</span></a>] [<a href="/pubmed/21079152" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21079152</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.oliveira.2013.722">Oliveira JB. The expanding spectrum of the autoimmune lymphoproliferative syndromes. <span><span class="ref-journal">Curr Opin Pediatr. </span>2013;<span class="ref-vol">25</span>:722–9.</span> [<a href="/pmc/articles/PMC4435794/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4435794</span></a>] [<a href="/pubmed/24240292" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24240292</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.oliveira.2007.8953">Oliveira JB, Bid&#x000e8;re N, Niemela JE, Zheng L, Sakai K, Nix CP, Danner RL, Barb J, Munson PJ, Puck JM, Dale J, Straus SE, Fleisher TA, Lenardo MJ. NRAS mutation causes a human autoimmune lymphoproliferative syndrome. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2007;<span class="ref-vol">104</span>:8953–8.</span> [<a href="/pmc/articles/PMC1885609/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1885609</span></a>] [<a href="/pubmed/17517660" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17517660</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.oliveira.2010.e35">Oliveira JB, Bleesing JJ, Dianzani U, Fleisher TA, Jaffe ES, Lenardo MJ, Rieux-Laucat F, Siegel RM, Su HC, Teachey DT, Rao VK. Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop. <span><span class="ref-journal">Blood. </span>2010;<span class="ref-vol">116</span>:e35–40.</span> [<a href="/pmc/articles/PMC2953894/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2953894</span></a>] [<a href="/pubmed/20538792" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20538792</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.pan.1997.815">Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. <span><span class="ref-journal">Science. </span>1997;<span class="ref-vol">277</span>:815–8.</span> [<a href="/pubmed/9242610" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9242610</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.peter.2005.25">Peter ME, Legembre P, Barnhart BC. Does CD95 have tumor promoting activities? <span><span class="ref-journal">Biochim Biophys Acta. </span>2005;<span class="ref-vol">1755</span>:25–36.</span> [<a href="/pubmed/15907590" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15907590</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.piqueras.2003.385">Piqueras B, Lavenu-Bombled C, Galicier L, Bergeron-van der Cruyssen F, Mouthon L, Chevret S, Debr&#x000e9; P, Schmitt C, Oksenhendler E. Common variable immunodeficiency patient classification based on impaired B cell memory differentiation correlates with clinical aspects. <span><span class="ref-journal">J Clin Immunol. </span>2003;<span class="ref-vol">23</span>:385–400.</span> [<a href="/pubmed/14601647" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14601647</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.poppema.2004.423">Poppema S, Maggio E, van den Berg A. Development of lymphoma in Autoimmune Lymphoproliferative Syndrome (ALPS) and its relationship to Fas gene mutations. <span><span class="ref-journal">Leuk Lymphoma. </span>2004;<span class="ref-vol">45</span>:423–31.</span> [<a href="/pubmed/15160902" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15160902</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.price.2014.1989">Price S, Shaw PA, Seitz A, Joshi G, Davis J, Niemela JE, Perkins K, Hornung RL, Folio L, Rosenberg PS, Puck JM, Hsu AP, Lo B, Pittaluga S, Jaffe ES, Fleisher TA, Rao VK, Lenardo MJ. Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations. <span><span class="ref-journal">Blood. </span>2014;<span class="ref-vol">123</span>:1989–99.</span> [<a href="/pmc/articles/PMC3968385/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3968385</span></a>] [<a href="/pubmed/24398331" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24398331</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.rao.2006.81">Rao VK, Carrasquillo JA, Dale JK, Bacharach SL, Whatley M, Dugan F, Tretler J, Fleisher T, Puck JM, Wilson W, Jaffe ES, Avila N, Chen CC, Straus SE. Fluorodeoxyglucose positron emission tomography (FDG-PET) for monitoring lymphadenopathy in the autoimmune lymphoproliferative syndrome (ALPS). <span><span class="ref-journal">Am J Hematol. </span>2006;<span class="ref-vol">81</span>:81–5.</span> [<a href="/pubmed/16432855" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16432855</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.rao.2011.5741">Rao VK, Oliveira JB. How I treat autoimmune lymphoproliferative syndrome. <span><span class="ref-journal">Blood. </span>2011;<span class="ref-vol">118</span>:5741–51.</span> [<a href="/pmc/articles/PMC3228494/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3228494</span></a>] [<a href="/pubmed/21885601" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21885601</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.rao.2009.847">Rao VK, Price S, Perkins K, Aldridge P, Tretler J, Davis J, Dale JK, Gill F, Hartman KR, Stork LC, Gnarra DJ, Krishnamurti L, Newburger PE, Puck J, Fleisher T. Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS). <span><span class="ref-journal">Pediatr Blood Cancer. </span>2009;<span class="ref-vol">52</span>:847–52.</span> [<a href="/pmc/articles/PMC2774763/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2774763</span></a>] [<a href="/pubmed/19214977" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19214977</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.rensingehl.2013.1948">Rensing-Ehl A, Janda A, Lorenz MR, Gladstone BP, Fuchs I, Abinun M, Albert M, Butler K, Cant A, Cseh AM, Ebinger M, Goldacker S, Hambleton S, Hebart H, Houet L, Kentouche K, K&#x000fc;hnle I, Lehmberg K, Mejstrikova E, Niemeyer C, Minkov M, Neth O, D&#x000fc;ckers G, Owens S, R&#x000f6;sler J, Schilling FH, Schuster V, Seidel MG, Smisek P, Sukova M, Svec P, Wiesel T, Gathmann B, Schwarz K, Vach W, Ehl S, Speckmann C. Sequential decisions on FAS sequencing guided by biomarkers in patients with lymphoproliferation and autoimmune cytopenia. <span><span class="ref-journal">Haematologica. </span>2013;<span class="ref-vol">98</span>:1948–55.</span> [<a href="/pmc/articles/PMC3856970/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3856970</span></a>] [<a href="/pubmed/23850805" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23850805</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.rensingehl.2010.357">Rensing-Ehl A, Warnatz K, Fuchs S, Schlesier M, Salzer U, Draeger R, Bondzio I, Joos Y, Janda A, Gomes M, Abinun M, Hambleton S, Cant A, Shackley F, Flood T, Waruiru C, Beutel K, Siepermann K, Dueckers G, Niehues T, Wiesel T, Schuster V, Seidel MG, Minkov M, Sirki&#x000e4; K, Kopp MV, Korhonen M, Schwarz K, Ehl S, Speckmann C. Clinical and immunological overlap between autoimmune lymphoproliferative syndrome and common variable immunodeficiency. <span><span class="ref-journal">Clin Immunol. </span>2010;<span class="ref-vol">137</span>:357–65.</span> [<a href="/pubmed/20832369" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20832369</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.revy.2000.565">Revy P, Muto T, Levy Y, Geissmann F, Plebani A, Sanal O, Catalan N, Forveille M, Dufourcq-Labelouse R, Gennery A, Tezcan I, Ersoy F, Kayserili H, Ugazio AG, Brousse N, Muramatsu M, Notarangelo LD, Kinoshita K, Honjo T, Fischer A, Durandy A. Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2). <span><span class="ref-journal">Cell. </span>2000;<span class="ref-vol">102</span>:565–75.</span> [<a href="/pubmed/11007475" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11007475</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.rieuxlaucat.1999.2575">Rieux-Laucat F, Blach&#x000e8;re S, Danielan S, De Villartay JP, Oleastro M, Solary E, Bader-Meunier B, Arkwright P, Pondar&#x000e9; C, Bernaudin F, Chapel H, Nielsen S, Berrah M, Fischer A, Le Deist F. Lymphoproliferative syndrome with autoimmunity: A possible genetic basis for dominant expression of the clinical manifestations. <span><span class="ref-journal">Blood. </span>1999;<span class="ref-vol">94</span>:2575–82.</span> [<a href="/pubmed/10515860" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10515860</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.rieuxlaucat.2003.325">Rieux-Laucat F, Fischer A, Deist FL. Cell-death signaling and human disease. <span><span class="ref-journal">Curr Opin Immunol. </span>2003;<span class="ref-vol">15</span>:325–31.</span> [<a href="/pubmed/12787759" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12787759</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.rieuxlaucat.1995.1347">Rieux-Laucat F, Le Deist F, Hivroz C, Roberts IA, Debatin KM, Fischer A, de Villartay JP. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. <span><span class="ref-journal">Science. </span>1995;<span class="ref-vol">268</span>:1347–9.</span> [<a href="/pubmed/7539157" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7539157</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.roberts.2013.1531">Roberts CA, Ayers L, Bateman EA, Sadler R, Magerus-Chatinet A, Rieux-Laucat F, Misbah SA, Ferry BL. Investigation of common variable immunodeficiency patients and healthy individuals using autoimmune lymphoproliferative syndrome biomarkers. <span><span class="ref-journal">Hum Immunol. </span>2013;<span class="ref-vol">74</span>:1531–5.</span> [<a href="/pubmed/23993982" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23993982</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.roesler.2005.1652">Roesler J, Izquierdo JM, Ryser M, R&#x000f6;sen-Wolff A, Gahr M, Valcarcel J, Lenardo MJ, Zheng L. Haploinsufficiency, rather than the effect of an excessive production of soluble CD95 (CD95{Delta}TM), is the basis for ALPS Ia in a family with duplicated 3' splice site AG in CD95 intron 5 on one allele. <span><span class="ref-journal">Blood. </span>2005;<span class="ref-vol">106</span>:1652–9.</span> [<a href="/pubmed/15870181" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15870181</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.r_ssler.2005.691">R&#x000f6;ssler J, Enders A, Lahr G, Heitger A, Winkler K, Fuchs H, Kopp M, Niemeyer C, Ehl S. Identical phenotype in patients with somatic and germline CD95 mutations requires a new diagnostic approach to autoimmune lymphoproliferative syndrome. <span><span class="ref-journal">J Pediatr. </span>2005;<span class="ref-vol">147</span>:691–4.</span> [<a href="/pubmed/16291365" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16291365</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.ruizgarc_a.2015.603">Ruiz-Garc&#x000ed;a R, Mora S, Lozano-S&#x000e1;nchez G, Mart&#x000ed;nez-Lostao L, Paz-Artal E, Ruiz-Contreras J, Anel A, Gonz&#x000e1;lez-Granado LI, Moreno-P&#x000e9;rez D, Allende LM. Decreased activation-induced cell death by EBV-transformed B-cells from a patient with autoimmune lymphoproliferative syndrome caused by a novel FASLG mutation. <span><span class="ref-journal">Pediatr Res. </span>2015;<span class="ref-vol">78</span>:603–8.</span> [<a href="/pubmed/26334989" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26334989</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.salzer.2013.3112">Salzer E, Santos-Valente E, Klaver S, Ban SA, Emminger W, Prengemann NK, Garncarz W, M&#x000fc;llauer L, Kain R, Boztug H, Heitger A, Arbeiter K, Eitelberger F, Seidel MG, Holter W, Pollak A, Pickl WF, F&#x000f6;rster-Waldl E, Boztug K. B-cell deficiency and severe autoimmunity caused by deficiency of protein kinase C &#x003b4;. <span><span class="ref-journal">Blood. </span>2013;<span class="ref-vol">121</span>:3112–6.</span> [<a href="/pmc/articles/PMC3630826/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3630826</span></a>] [<a href="/pubmed/23319571" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23319571</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.savic.2015.502">Savic S, Parry D, Carter C, Johnson C, Logan C, Gutierrez BM, Thomas JE, Bacon CM, Cant A, Hambleton S. A new case of Fas-associated death domain protein deficiency and update on treatment outcomes. <span><span class="ref-journal">J Allergy Clin Immunol. </span>2015;<span class="ref-vol">136</span>:502–5.e4.</span> [<a href="/pubmed/25794656" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25794656</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.schneider.1997.831">Schneider P, Thome M, Burns K, Bodmer JL, Hofmann K, Kataoka T, Holler N, Tschopp J. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. <span><span class="ref-journal">Immunity. </span>1997;<span class="ref-vol">7</span>:831–6.</span> [<a href="/pubmed/9430228" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9430228</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.schubert.2014.1410">Schubert D, Bode C, Kenefeck R, Hou TZ, Wing JB, Kennedy A, Bulashevska A, Petersen BS, Sch&#x000e4;ffer AA, Gr&#x000fc;ning BA, Unger S, Frede N, Baumann U, Witte T, Schmidt RE, Dueckers G, Niehues T, Seneviratne S, Kanariou M, Speckmann C, Ehl S, Rensing-Ehl A, Warnatz K, Rakhmanov M, Thimme R, Hasselblatt P, Emmerich F, Cathomen T, Backofen R, Fisch P, Seidl M, May A, Schmitt-Graeff A, Ikemizu S, Salzer U, Franke A, Sakaguchi S, Walker LS, Sansom DM, Grimbacher B. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. <span><span class="ref-journal">Nat Med. </span>2014;<span class="ref-vol">20</span>:1410–6.</span> [<a href="/pmc/articles/PMC4668597/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4668597</span></a>] [<a href="/pubmed/25329329" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25329329</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.seif.2010.2142">Seif AE, Manno CS, Sheen C, Grupp SA, Teachey DT. Identifying autoimmune lymphoproliferative syndrome in children with Evans syndrome: a multi-institutional study. <span><span class="ref-journal">Blood. </span>2010;<span class="ref-vol">115</span>:2142–5.</span> [<a href="/pubmed/20068224" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20068224</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.shah.2014.462">Shah S, Wu E, Rao VK, Tarrant TK. Autoimmune lymphoproliferative syndrome: an update and review of the literature. <span><span class="ref-journal">Curr Allergy Asthma Rep. </span>2014;<span class="ref-vol">14</span>:462–4.</span> [<a href="/pmc/articles/PMC4148697/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4148697</span></a>] [<a href="/pubmed/25086580" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25086580</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.siegel.2000.2354">Siegel RM, Frederiksen JK, Zacharias DA, Chan FK, Johnson M, Lynch D, Tsien RY, Lenardo MJ. Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. <span><span class="ref-journal">Science. </span>2000;<span class="ref-vol">288</span>:2354–7.</span> [<a href="/pubmed/10875918" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10875918</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.sleight.1998.375">Sleight BJ, Prasad VS, DeLaat C, Steele P, Ballard E, Arceci RJ, Sidman CL. Correction of autoimmune lymphoproliferative syndrome by bone marrow transplantation. <span><span class="ref-journal">Bone Marrow Transplant. </span>1998;<span class="ref-vol">22</span>:375–80.</span> [<a href="/pubmed/9722073" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9722073</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.sneller.1992.334">Sneller MC, Straus SE, Jaffe ES, Jaffe JS, Fleisher TA, Stetler-Stevenson M, Strober W. A novel lymphoproliferative/autoimmune syndrome resembling murine lpr/gld disease. <span><span class="ref-journal">J Clin Invest. </span>1992;<span class="ref-vol">90</span>:334–41.</span> [<a href="/pmc/articles/PMC443107/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC443107</span></a>] [<a href="/pubmed/1386609" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1386609</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.snow.2008.34">Snow AL, Oliveira JB, Zheng L, Dale JK, Fleisher TA, Lenardo MJ. Critical role for BIM in T cell receptor restimulation-induced death. <span><span class="ref-journal">Biol Direct. </span>2008;<span class="ref-vol">3</span>:34.</span> [<a href="/pmc/articles/PMC2529272/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2529272</span></a>] [<a href="/pubmed/18715501" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18715501</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.sobh.2016.324">Sobh A, Crestani E, Cangemi B, Kane J, Chou J, Pai SY, Notarangelo LD, Al-Herz W, Geha RS, Massaad MJ. Autoimmune lymphoproliferative syndrome caused by a homozygous FasL mutation that disrupts FasL assembly. <span><span class="ref-journal">J Allergy Clin Immunol. </span>2016;<span class="ref-vol">137</span>:324–7.</span> [<a href="/pubmed/26456038" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26456038</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.straus.2001.194">Straus SE, Jaffe ES, Puck JM, Dale JK, Elkon KB, R&#x000f6;sen-Wolff A, Peters AM, Sneller MC, Hallahan CW, Wang J, Fischer RE, Jackson CM, Lin AY, B&#x000e4;umler C, Siegert E, Marx A, Vaishnaw AK, Grodzicky T, Fleisher TA, Lenardo MJ. The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. <span><span class="ref-journal">Blood. </span>2001;<span class="ref-vol">98</span>:194–200.</span> [<a href="/pubmed/11418480" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11418480</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.takagi.2011.2887">Takagi M, Shinoda K, Piao J, Mitsuiki N, Takagi M, Matsuda K, Muramatsu H, Doisaki S, Nagasawa M, Morio T, Kasahara Y, Koike K, Kojima S, Takao A, Mizutani S. Autoimmune lymphoproliferative syndrome-like disease with somatic KRAS mutation. <span><span class="ref-journal">Blood. </span>2011;<span class="ref-vol">117</span>:2887–90.</span> [<a href="/pubmed/21063026" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21063026</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.teachey.2012.1">Teachey DT. New advances in the diagnosis and treatment of autoimmune lymphoproliferative syndrome. <span><span class="ref-journal">Curr Opin Pediatr. </span>2012;<span class="ref-vol">24</span>:1–8.</span> [<a href="/pmc/articles/PMC3673763/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3673763</span></a>] [<a href="/pubmed/22157362" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22157362</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.teachey.2009.101">Teachey DT, Greiner R, Seif A, Attiyeh E, Bleesing J, Choi J, Manno C, Rappaport E, Schwabe D, Sheen C, Sullivan KE, Zhuang H, Wechsler DS, Grupp SA. Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome. <span><span class="ref-journal">Br J Haematol. </span>2009;<span class="ref-vol">145</span>:101–6.</span> [<a href="/pmc/articles/PMC2819393/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2819393</span></a>] [<a href="/pubmed/19208097" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19208097</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.vaishnaw.1999.1833">Vaishnaw AK, Toubi E, Ohsako S, Drappa J, Buys S, Estrada J, Sitarz A, Zemel L, Chu JL, Elkon KB. The spectrum of apoptotic defects and clinical manifestations, including systemic lupus erythematosus, in humans with CD95 (Fas/APO-1) mutations. <span><span class="ref-journal">Arthritis Rheum. </span>1999;<span class="ref-vol">42</span>:1833–42.</span> [<a href="/pubmed/10513797" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10513797</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.van_der_burg.2000.336">van der Burg M, de Groot R, Comans-Bitter WM, den Hollander JC, Hooijkaas H, Neijens HJ, Berger RM, Oranje AP, Langerak AW, van Dongen JJ. Autoimmune lymphoproliferative syndrome (ALPS) in a child from consanguineous parents: a dominant or recessive disease? <span><span class="ref-journal">Pediatr Res. </span>2000;<span class="ref-vol">47</span>:336–43.</span> [<a href="/pubmed/10709732" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10709732</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.van_der_werff_ten_bosch.1999.1045">van der Werff ten Bosch J, Delabie J, B&#x000f6;hler T, Verschuere J, Thielemans K. Revision of the diagnosis of T-zone lymphoma in the father of a patient with autoimmune lymphoproliferative syndrome type II. <span><span class="ref-journal">Br J Haematol. </span>1999;<span class="ref-vol">106</span>:1045–8.</span> [<a href="/pubmed/10520011" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10520011</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.vincenz.1997.6578">Vincenz C, Dixit VM. Fas-associated death domain protein interleukin-1beta-converting enzyme 2 (FLICE2), an ICE/Ced-3 homologue, is proximally involved in CD95- and p55-mediated death signaling. <span><span class="ref-journal">J Biol Chem. </span>1997;<span class="ref-vol">272</span>:6578–83.</span> [<a href="/pubmed/9045686" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9045686</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.wang.2001.13884">Wang J, Chun HJ, Wong W, Spencer DM, Lenardo MJ. Caspase-10 is an initiator caspase in death receptor signaling. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2001;<span class="ref-vol">98</span>:13884–8.</span> [<a href="/pmc/articles/PMC61136/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC61136</span></a>] [<a href="/pubmed/11717445" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11717445</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.wang.1999.47">Wang J, Zheng L, Lobito A, Chan FK, Dale J, Sneller M, Yao X, Puck JM, Straus SE, Lenardo MJ. Inherited human Caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II. <span><span class="ref-journal">Cell. </span>1999;<span class="ref-vol">98</span>:47–58.</span> [<a href="/pubmed/10412980" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10412980</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.warnatz.2002.1544">Warnatz K, Denz A, Dr&#x000e4;ger R, Braun M, Groth C, Wolff-Vorbeck G, Eibel H, Schlesier M, Peter HH. Severe deficiency of switched memory B cells (CD27(+)IgM(-)IgD(-)) in subgroups of patients with common variable immunodeficiency: a new approach to classify a heterogeneous disease. <span><span class="ref-journal">Blood. </span>2002;<span class="ref-vol">99</span>:1544–51.</span> [<a href="/pubmed/11861266" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11861266</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.wu.1996.1107">Wu J, Wilson J, He J, Xiang L, Schur PH, Mountz JD. Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. <span><span class="ref-journal">J Clin Invest. </span>1996;1996;<span class="ref-vol">98</span>:1107–13.</span> [<a href="/pmc/articles/PMC507531/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC507531</span></a>] [<a href="/pubmed/8787672" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8787672</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="alps.REF.zhu.2006.284">Zhu S, Hsu AP, Vacek MM, Zheng L, Sch&#x000e4;ffer AA, Dale JK, Davis J, Fischer RE, Straus SE, Boruchov D, Saulsbury FT, Lenardo MJ, Puck JM. Genetic alterations in caspase-10 may be causative or protective in autoimmune lymphoproliferative syndrome. <span><span class="ref-journal">Hum Genet. </span>2006;<span class="ref-vol">119</span>:284–94.</span> [<a href="/pubmed/16446975" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16446975</span></a>]</div></li></ul></div></div><div id="alps.Chapter_Notes"><h2 id="_alps_Chapter_Notes_">Chapter Notes</h2><div id="alps.Author_History"><h3>Author History</h3><p>Jack JH Bleesing, MD, PhD (2006-present)<br />Judith Johnson, MS, CGC; Cincinnati Children's Hospital (2006-2017)<br />Chinmayee Nagaraj, MS, CGC (2017-present)<br />Kejian Zhang, MD, MBA (2006-present)</p></div><div id="alps.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>24 August 2017 (ha) Comprehensive update posted live</div></li><li class="half_rhythm"><div>11 September 2014 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>8 September 2011 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>7 April 2009 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>9 July 2007 (cd) Revision: <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> and <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> available clinically for <i>CASP10</i></div></li><li class="half_rhythm"><div>14 September 2006 (me) Review posted live</div></li><li class="half_rhythm"><div>2 December 2005 (jj) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1108</span><span class="label">PMID: <a href="/pubmed/20301287" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301287</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/au-kline/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/peaf/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1108&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1108/?report=reader">PubReader</a></li><li><a href="/books/NBK1108/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1108" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1108" style="display:none" title="Cite this Page"><div class="bk_tt">Bleesing JJH, Nagaraj CB, Zhang K. Autoimmune Lymphoproliferative Syndrome. 2006 Sep 14 [Updated 2017 Aug 24]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1108/pdf/Bookshelf_NBK1108.pdf">PDF version of this page</a> (733K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#alps.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#alps.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#alps.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#alps.Genetically_Related_Allelic_Disorde" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#alps.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#alps.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#alps.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#alps.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#alps.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#alps.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#alps.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=356[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">FASLG</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=843[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">CASP10</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=355[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">FAS</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Variations in ClinVar</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=NBK1108+AND+genereviews[submitter]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Variations from this GeneReview in ClinVar</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1492050" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1492050" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1492050" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1492050" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/21447005" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Advances in autoimmune lymphoproliferative syndromes.</a><span class="source">[Eur J Haematol. 2011]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Advances in autoimmune lymphoproliferative syndromes.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Madkaikar M, Mhatre S, Gupta M, Ghosh K. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Eur J Haematol. 2011 Jul; 87(1):1-9. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301541" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Genetic Atypical Hemolytic-Uremic Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Genetic Atypical Hemolytic-Uremic Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Noris M, Bresin E, Mele C, Remuzzi G. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301575" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Fanconi Anemia</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Fanconi Anemia<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Mehta PA, Tolar J. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301446" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Gaucher Disease</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Gaucher Disease<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Pastores GM, Hughes DA. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/26323380" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Autoimmune lymphoproliferative syndrome due to somatic FAS mutation (ALPS-sFAS) combined with a germline caspase-10 (CASP10) variation.</a><span class="source">[Immunobiology. 2016]</span><div class="brieflinkpop offscreen_noflow">Autoimmune lymphoproliferative syndrome due to somatic FAS mutation (ALPS-sFAS) combined with a germline caspase-10 (CASP10) variation.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Martínez-Feito A, Melero J, Mora-Díaz S, Rodríguez-Vigil C, Elduayen R, González-Granado LI, Pérez-Méndez D, Sánchez-Zapardiel E, Ruiz-García R, Menchén M, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Immunobiology. 2016 Jan; 221(1):40-7. Epub 2015 Aug 17.</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301287" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301287" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e04293bdd21425a259c2d61">Autoimmune Lymphoproliferative Syndrome - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Autoimmune Lymphoproliferative Syndrome - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T22:30:03-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal103&amp;ncbi_phid=CE8A1EE9E0414151000000000952036A&amp;ncbi_session=CE8A1EE9E04293A1_2386SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1108%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1108&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1108/&amp;ncbi_pagename=Autoimmune Lymphoproliferative Syndrome - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8A1EE9E04293A1_2386SID /projects/books/PBooks@5.22 portal103 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>